US20090317401A1 - Angiogenic and immunoglobic applications of anti cd160 specific compounds obtainable from mab cl 1-r2 - Google Patents

Angiogenic and immunoglobic applications of anti cd160 specific compounds obtainable from mab cl 1-r2 Download PDF

Info

Publication number
US20090317401A1
US20090317401A1 US11/659,749 US65974905A US2009317401A1 US 20090317401 A1 US20090317401 A1 US 20090317401A1 US 65974905 A US65974905 A US 65974905A US 2009317401 A1 US2009317401 A1 US 2009317401A1
Authority
US
United States
Prior art keywords
cells
mab
compound
shla
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/659,749
Other languages
English (en)
Inventor
Armand Bensussan
Laurence Boumsell
Philippe Le Bouteiller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Assigned to INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) reassignment INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BENSUSSAN, ARMAND, LEBOUTEILLER, PHILIPPE, BOUMSELL, LAURENCE
Publication of US20090317401A1 publication Critical patent/US20090317401A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2836—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD106
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Definitions

  • the present invention relates to an anti-CD160 specific mAb (CL1-R2 accessible under hybridoma deposit number CNCM I-3204), to anti-CD160 specific compounds deriving therefrom, and to the biological and medical applications of such anti-CD160 compounds and mAb.
  • the present invention more particularly relates to means for specifically controlling and regulating:
  • mAb monoclonal antibody
  • CL1-R2 hybrida Budapest Treaty deposit CNCM I-3204
  • the present invention indeed demonstrates that the receptor CD160 (previously also referred to as BY55), which is known to be expressed by cytotoxic NK and T subsets (CD56 dim CD16 bright CD3 ⁇ NK; T CD8+; TCR ⁇ ), is involved in both angiogenesis and immune system regulation.
  • CD160 structure has been extensively described in prior art documents, see e.g. WO 98/21240 in the name of the DANA-FARBER CANCER INSTITUTE.
  • Angiogenesis the formation of new capillaries from the preexisting blood vessels, is a crucial component of embryonic vascular development and differentiation, wound healing, and organ regeneration. It however also contributes to the progression of pathologies that depends on neovascularization, including tumor growth, diabetes, ischemic ocular diseases, and rheumatoid arthritis (Risau, 1997; Ferrara, 1997). While the most important mediators of angiogenesis, the vascular endothelial cell growth factor (VEGF) family and fibroblast growth factor family are well define, angiogenesis stands as a complex process involving multiple gene products expressed by different cell types all contributing to an integrated sequence of events.
  • VEGF vascular endothelial cell growth factor
  • WO 03/018048 in the name of ABTECH et al. relates to the use of two soluble HLA Class I molecules, namely sHLA-G1 and sHLA-B7, to inhibit angiogenesis or to detect angiogenic sites. Supportive to this anti-angiogenic effect is the demonstration that sHLA-G1 inhibits endothelial cells (EC) proliferation and migration. It is also shown that sHLA-G1 and sHLA-B7 may inhibit the progression of a tumor induced by grafting human prostate adenocarcinoma cells in nude mice.
  • sHLA-G1 and sHLA-B7 may inhibit the progression of a tumor induced by grafting human prostate adenocarcinoma cells in nude mice.
  • WO 03/018048 also mentions that an anti-CD160 antibody referred to as CL1-R2 inhibits the action exerted by sHLA-G on EC migration. It is therefrom deduced that BY55 could be an endothelial receptor for sHLA-G (cf. WO 03/018048 as published, page 23 lines 3-8).
  • soluble HLA such as sHLA-G1 and sHLA-B7, are natural ligands for numerous receptors.
  • NK cells constitute a subset of lymphocytes that play a role in innate immunity directed against virally-infected or tumor cells. Their effector functions are the killing of target cells and cytokine production. NK cells use a combination of inhibitory and activating receptors expressed at their cell surface to mediate target cell killing and cytokine release upon interaction with specific ligands. Upon specific engagement with these ligands present on target cells, they release cytolytic granules containing perform and granzyme that contribute to target cell apoptosis. Upon contact with sensitive target cells, they also produce a number of cytokines, including IFN- ⁇ , TNF- ⁇ and GM-CSF early in the innate immune response that modulate adaptive immunity by regulating T cell function.
  • cytokines including IFN- ⁇ , TNF- ⁇ and GM-CSF early in the innate immune response that modulate adaptive immunity by regulating T cell function.
  • IFN- ⁇ secreted by uterine NK cells may also control placental development and vascularisation during pregnancy.
  • KIR2DL4 (CD158d) induces IFN- ⁇ , production in resting and activated NK cells.
  • CD16 is a low-affinity Fc ⁇ RIII receptor responsible for Ab-dependent cellular cytotoxicity (ADCC). Signaling via CD16 triggers the production of cytokines, including IFN- ⁇ , GM-CSF, and several chemokines. Incubation of activated NK cells with anti-NKp30 or anti-NKp46 mAb led to IFN- ⁇ production by NK cells.
  • Human NKG2D activating receptor that recognizes the stress-induced MICA and MICB molecules as well as the ULBP family of molecules and plays a major role in NK cell-mediated cytotoxicity is apparently unable to produce cytokines once triggered by specific mAbs.
  • T cells including CD8+ and CD4+ T cells also produce cytokines.
  • Th1 cells produce IL-2 and IFN- ⁇
  • Th2 cells produce IL-4.
  • the effector functions of CD8+ T cells partially overlap those of CD4+ T cells.
  • Naive T cells can differentiate into at least two subsets with distinct cytokine patterns: T-cytotoxic 1 cells secrete a Th1-like cytokine pattern, while T cytotoxic 2 cells secrete Th2 cytokines.
  • IFN- ⁇ to represent a typical type 1 cytokine
  • the signature cytokine of type 2 response is IL-4.
  • Cytokines intervene in the differentiation and stimulation of antibody-producing B cell clones and the cytopathic action of cytotoxic T cells. Likewise, cytokine secretion influences the cell-destroying capacity of NK cells, and the capacity of macrophages to phagocytose different bacterial plaque components.
  • the present invention provides with means for specifically controlling up- or down-regulation of cytokine production.
  • the means specifically acts on the CD160 signaling pathways.
  • CD160 is the only non-clonally expressed receptor on the majority of circulating NK cells.
  • CD160+ cells correspond to the non-proliferating, highly cytolytic, CD56 dim CD16 + NK subset.
  • CD160 engagement by HLA-C molecules mediates cytotoxic function.
  • CD160 is expressed by circulating CD56 dim CD 16 bright CD3 ⁇ NK, which constitute the majority of PB-NK cells.
  • CD56 dim NK cell subset is more naturally cytotoxic and produces less abundant cytokines than CD 56 bright subset following activation by monocytes.
  • CD56 dim NK cell subset also expresses a specific pattern of chemokine receptors and adhesion molecules. Such phenotype is characteristic of terminally differentiated effector cells.
  • CD160 + NK cells have a high cytotoxic activity potential, do not proliferate to IL-2, and mediate cell lysis upon interaction with HLA-C.
  • CD160 receptor appears unique for the following reasons. It is encoded by a gene located on human chromosome 1, it is a glycosyl phosphatydil inositol (GPI)-anchored molecule and its cell surface expression is down-modulated by NK cell activation mediated by cytokines including IL-2 and IL-15. As described for the killer cell Ig-like inhibitory receptors, CD160 is also expressed by ⁇ T cells, and a subset of ⁇ CD8+ T cell.
  • GPI glycosyl phosphatydil inositol
  • the present invention relates to an anti-CD160 monoclonal antibody (mAb CL1-R2 obtainable from hybridoma TM60 accessible under CNCM deposit number I-3204) and to the conservative anti-CD160 equivalents thereof.
  • mAb CL1-R2 obtainable from hybridoma TM60 accessible under CNCM deposit number I-3204
  • the present invention indeed demonstrates that CD160 is expressed by endothelial cells (EC), and the anti-CD160 compounds of the invention can act as CD160 activating ligands. Stimulation of the CD160 signaling pathway by the anti-CD160 compounds of the invention induces an anti-angiogenic effect.
  • EC endothelial cells
  • the present invention also demonstrate that CD160 is expressed not only by the cytotoxic NK and T subsets, but also by CD4+ T cells cultured with IL-15 (expressing cytotoxic activity), and that CD160 stimulation by aggregated anti-CD160 compounds of the invention leads to cytokine production.
  • the cytokine profile that is thus obtained is unique compared to those obtained by stimulation of other NK-expressed receptors. It is also unique in the sense that it is very closely mimicking the cytokine profile induced by CD160 stimulation with natural ligands (membrane bound HLA).
  • These cytokines notably comprise IFN- ⁇ , TNF- ⁇ and IL-6.
  • Cytokine production induced by cell membrane HLA molecules can be inhibited using either the anti-CD160 compounds of the invention in soluble form, or anti-CD160 compounds of the invention which comprise at least one CD158b binding site in addition to their CD160 binding site(s).
  • the present invention hence encompasses the hybridoma TM60 as such, the CL1-R2 monoclonal antibody (mAb), the anti-CD160 compounds of the invention, any composition or kit comprising them, and any drug containing at least one of them.
  • the present invention also relates to means enabling the identification of CD160 ligands, CD160 membrane-associated molecules, and CD160 cytosol second messengers.
  • the present invention gives a publicly available source of an anti-CD160 specific monoclonal antibody (mAb), which is referred to by the inventors as CL1-R2.
  • mAb anti-CD160 specific monoclonal antibody
  • a CL1-R2 producing hybridoma has been deposited at the Collection Nationale de Cultures de Microorganismes C.N.C.M. Institut Pasteur in accordance with the terms of the Budapest Treaty on Apr. 28, 2004 (C.N.C.M. Institut Pasteur 25, rue du Dondel Roux F-75724 Paris Cedex 15 France).
  • the deposited hybridoma has CNCM deposit number I-3204.
  • the present invention hence relates to the hybridoma TM60 accessible under CNCM deposit number 1-3204, as well as to the anti-CD160 mAb obtainable therefrom (CL1-R2).
  • the present invention also provides with anti-CD160 compounds obtainable from said CL1-R2 mAb, e.g. as CL1-R2 fragments or derivatives.
  • the inventors further provide demonstrations relating to:
  • the present invention provides the demonstration that CD160, a receptor which up to now was known to be expressed by a cytotoxic subset of NK cells and by CD8+ and TCR ⁇ T cells, is also expressed by endothelial cells (EC) as a membrane receptor, and that CD160 mediates HLA anti-angiogenic signaling.
  • CD160 a receptor which up to now was known to be expressed by a cytotoxic subset of NK cells and by CD8+ and TCR ⁇ T cells
  • EC endothelial cells
  • the present invention also demonstrates that the anti-CD160 mAb that was said in WO 03/018048 to inhibit HLA-G action on EC does in fact not inhibit it, but mimics it.
  • the present invention further demonstrates that the binding of, and preferably the cross-linking of CD160 by appropriate anti-CD160 compounds inhibit the vessel formation and growth that is induced by pro-angiogenic factors such as VEGF or FGF2 on EC.
  • the present invention thus provides the first direct demonstration that the formation of new capillaries can actually be regulated and controlled, and also provides industrially effective means therefor.
  • the present invention hence provides actual pharmaceutical and medical applications.
  • Such applications notably include the prevention, symptom alleviation or treatment of those pathologies or conditions which are due to, or favored by an activity of neo-vascularization. Under these circumstances, neo-vascularization is acting as a pro-pathologic component. The activity of neo-vascularization is then considered to represent an undesired activity, or to be at an excessive level.
  • neo-vascularization-feeded pathologies or conditions notably comprise tumor growth (e.g. the growth of tumors), diabetes, ischemic ocular diseases, and rheumatoid arthritis. They also include pre-eclampsia or eclampsia, which are characterized by an insufficient blood supply at the fetus-placenta interface (insufficient or inappropriate endovascular trophoblast invasion of maternal spiral arteries).
  • appropriate means include those anti-CD160 compounds that have an affinity for binding to CD160 that is sufficiently high to compete with CL1-R2 for binding to CD160.
  • CL1-R2 is the anti-CD160 mAb that is produced by the hybridoma accessible under CNCM deposit number I-3204.
  • CL1-R2 When it relates to EC-expressed CD160, CL1-R2 can be used in soluble form, as well as in aggregated form. Both forms induce signal transduction upon binding to CD160 (i.e. transduction of a signal of angiogenesis inhibition).
  • the aggregated form simply has a higher affinity for binding to CD160 than the soluble form.
  • Anti-CD160 mAb have the special technical advantage of having a specificity that HLA ligands do not have. If they were administered to a living organism, such as e.g. a human being, HLA ligands would bind to CD160 as well as to many other receptors, and would thereby induce completely uncontrolled chain reactions in said organism. On a therapeutic point of a view, HLA ligands hence have no proven industrial applicability.
  • Anti-CD160 mAbs such as CL1-R2 are specific of CD160, i.e. they have a CD160 affinity that is sufficient for them to bind essentially only to CD160, at least under in vivo-like conditions. Hence, contrary to HLA ligands, anti-CD160 mAbs have industrial applicability as therapeutic agents.
  • the present invention hence provides for the first time agents which are able to act on CD160 as activating ligands, and which are also usable as agents to be administered in a living organism in need of a CD160 activating treatment.
  • the present invention provides the first therapeutically-compliant CD160 activating agents.
  • Such appropriate anti-CD160 candidate ligands include CL1-R2 itself as well as conservative fragments and derivatives thereof.
  • An aspect of the present invention also resides in the fact that it now provides the demonstration that CD160 is not expressed by tumor cells (Lewis lung carcinoma cells), but that those EC that surrounds or infiltrates tumors actually express CD160.
  • the anti-CD160 mAbs as well as conservative fragments and derivatives of the invention can be used as therapeutic agents against malignant cells such as B-cell chronic lymphocytic leukemia (CLL) which expressed CD160 molecules at their cell membrane.
  • CLL B-cell chronic lymphocytic leukemia
  • the anti-CD160 compounds of the invention hence are very useful means for preventing, treating, or alleviating the symptoms of a tumor development.
  • the present invention also provides means to identify pharmaceutically useful compounds by screening for binding to CD160, and/or by screening for CD160-specific membrane-bound or cytosolic effectors. Such effectors represent useful target for anti-angiogenic therapy.
  • CD160 belongs to the immunoglobulin supergene family. Descriptive information on CD160 can be found on http://www.ncbi.nlm.nih.gov/prow/guide/1660590458_g.htm.
  • the cDNA sequence of human CD160 is described as SEQ ID NO:1 (1361 bp) in WO 98/21240 (DANA-FARBER CANCER INSTITUTE).
  • the mRNA sequence of human CD160 is available from Genbank under AF060981 accession number, the mRNA sequence of mouse CD160 has AF060982 Genbank accession number.
  • the protein sequence of human CD160 is described as SEQ ID NO:2 in said WO 98/21240, and is also available from Genbank under AAC72302 accession number (181 aa).
  • CD160 nucleic acids can be isolated from CD160-expressing cells following any routine procedure that is available to the skilled person [see e.g. the procedures disclosed in Molecular Cloning, A Laboratory Manual (2 nd Ed., Sambrook, Fritsch and Maniatis, Cold Spring Harbor); Current Protocols in Molecular Biology (Eds. Aufubel, Brent, Kingston, More, Feldman, Smith and Sea, Greene Publ. Assoc., Wiley-Interscience, NY, N.Y. 1992].
  • Naturally-occurring CD160-expressing cells can notably be found within cytolytic NK and T cells (such as CD56 dim CD16 + NK cells and TCR ⁇ and TCR ⁇ + CD8 bright CD95 + CD56 + CD28 ⁇ CD27 ⁇ cells), as well as in accordance with the present invention within epithelial cells and cytotoxic CD4+ T cells.
  • cytolytic NK and T cells such as CD56 dim CD16 + NK cells and TCR ⁇ and TCR ⁇ + CD8 bright CD95 + CD56 + CD28 ⁇ CD27 ⁇ cells
  • Isolated CD160 proteins and polypeptides are available following any routine procedure that is available to the skilled person, such as by isolation from CD160-expressing cells, or by recombinant production (see the above-mentioned reference manuals—Molecular Cloning, A Laboratory Manual; Current Protocols in Molecular Biology).
  • CD160 protein is of course also available in non-isolated forms, as access to a CD160 protein can be achieved through the provision of a cell expressing CD160.
  • Cells expressing CD160 as a membrane receptor thus also provide access to a non-isolated form of CD160.
  • cells expressing CD160 as a membrane receptor are a preferred source of CD160 material.
  • examples of such cells notably include NK cells and T cells with cytolytic activity or EC cells or cytotoxic CD4+ T cells collected from human beings, as well as cell lines such as NK92 (ATCC CRL-2407), HUVEC or human microvascular endothelial cells (HMVEC) (Cambrex Bio Science, Walkersville, Md.).
  • CD160 proteins or polypeptides can also be provided in a clustered form.
  • CD 160 proteins or polypeptides can for example be bound to a solid support, preferably a biologically-inactive solid support, e.g. CD160-coated beads.
  • the present invention hence relates to anti-CD160 compounds, and to the medical and/or biological applications thereof.
  • the anti-CD160 compounds of the invention bind to CD160 substantially on the same epitope than CL1-R2, and preferably are capable of competing with the anti-CD160 mAb CL1-R2 (obtainable from the hybridoma deposited as CNCM I-3204) for binding to CD160.
  • the anti-CD160 compounds of the invention are sufficiently CD160-specific for binding to CD160 without binding to at least one HLA receptor other than CD160, such as e.g. CD8 ⁇ .
  • the present invention further relates to a pharmaceutical composition
  • a pharmaceutical composition comprising at least one anti-CD160 compound of the invention, wherein said composition is intended for use in an anti-angiogenic therapy, and notably to an anti-angiogenic drug.
  • the present invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising at least one anti-CD160 compound of the invention, wherein said composition is intended for the detection of anti-angiogenic sites, and/or for the diagnosis and/or prognosis of a disease or condition involving angiogenesis.
  • the anti-CD160 compounds of the invention include the anti-CD160 mAb CL1-R2 itself.
  • CL1-R2 has proven very effective in inducing an anti-angiogenic effect upon binding to CD160, whereas prior art anti-CD160 mAb has proven ineffective.
  • targeting the correct CD160 epitope on CD160 is crucial to obtain the desired effect, namely targeting an epitope essentially similar to the one onto which CL1-R2 binds.
  • the anti-CD160 compounds of the invention preferably bind to CD160 on an epitope that is essentially similar to the one onto which CL1-R2 binds.
  • the anti-CD160 compounds of the invention bind to human CD160.
  • Unspecific binding can induce undesired side effects in the organism receiving an anti-CD160 compound. More particularly, if a sHLA such as sHLA-G were to be administered to a patient in need of an anti-angiogenic effect (for example, a patient having a tumor), said sHLA would bind to CD160 and induce the desired anti-angiogenic effect on EC, but would also bind to many other receptors expressed by a diversity of different cells within said patient A sHLA such as sHLA-G would notably bind to CD8 ⁇ expressed by T cells, and induce apoptosis of these T cells. Such an anti-T effect is highly undesirable to the patient suffering from a disease such as cancer.
  • the present invention provides for the first time an anti-CD160 compound which is sufficiently CD160-specific to induce an anti-angiogenesis on EC, without inducing undesired or uncontrolled side effects, such as e.g. apoptosis of T cells.
  • the anti-CD160 compounds of the invention preferably do not bind to human CD8 ⁇ .
  • Such conservative fragments and derivatives have retained the desired binding affinity and specificity, i.e. they are qualified to be “conservative” because they still bind to substantially the same epitope as CL1-R2 and/or can compete with CL1-R2 for binding to CD160, and have retained a sufficient CD160 specificity, such as e.g. a sufficient CD160 specificity for not binding to at least one HLA receptor other than CD160, such as CD8 ⁇ .
  • the anti-CD160 compound of the invention does not bind to the T- and NK-expressed receptor CD85j (also referred to as ILT-2). Preferably, they do not bind to human CD85j.
  • the anti-CD160 compound of the invention does not cross-react with any EC receptor other than CD160.
  • the anti-CD160 compounds of the invention are fully CD160-specific, in the sense that they do not cross-react with any classical and non classical HLA molecule receptor with either allele or broad specificity.
  • These receptors include CD8 ⁇ , CD94 associated with each of the NKG2 family gene products (located on chromosome 12), and all the products of the genes located on chromosome 19 including KIR and ILT/LIR families.
  • Binding or absence of binding of an anti-CD160 compound of the invention to a receptor is meant as binding or absence of binding as would be observed under physiological conditions, or under in vitro conditions mimicking in vivo conditions. Any mean and/or procedure that the skilled person would find appropriate to perform said binding assay is suitable for determining whether a compound binds to CD160, does not bind to any other EC receptor, does not bind to CD8 ⁇ , and does not bind to CD85j.
  • Illustrative conditions comprise providing a cell expressing the desired target, such as an EC (expressing CD160 and other EC receptors), or a CD8+ T (expressing CD160 and CD8 ⁇ ), or as will be shown below CD4+ T cells (expressing CD160 as demonstrated by the present invention), and contacting said CD160-expressing cell with the compound under conditions of compound concentration, contact duration, pH, and temperature that would enable binding of the cell-expressed target by its natural ligand.
  • a cell expressing the desired target such as an EC (expressing CD160 and other EC receptors), or a CD8+ T (expressing CD160 and CD8 ⁇ ), or as will be shown below CD4+ T cells (expressing CD160 as demonstrated by the present invention)
  • CD4+ T cells expressing CD160 as demonstrated by the present invention
  • Illustrative techniques to assess whether a compound binds to CD160 but not to at least one other HLA receptor, such as CD8 ⁇ notably comprise:
  • Sources of CD160-expressing cells comprise EC collected from a healthy individual, or EC from a cell line such as NK92 (ATCC Number CRL-2407), HUVEC, HMVEC (Cambrex Bio Science, Walkersville, Md., U.S.A.).
  • Sources of CD8 ⁇ -expressing cells comprise CD8+ T cells, such as CD8+ T cells collected from a healthy individual, or CD8+ T cells from a cell line such as MOLT-4 (ATCC Number CRL-1582).
  • Sources of CD85j-expressing cells comprise CD85j+ T cells, such as CD85j+ T cells or monocytes collected from a healthy individual, or CD85j+ T cells from a cell line such as NAMALWA (ATCC Number CRL-1432).
  • Preferred sources are those which express the human form of the target receptor.
  • the human sequence of CD160 is available from the NCBI data bank under accession numbers NM — 007053 (nucleic acid) and CAG46686 (protein)
  • the human sequence of CD8 ⁇ is available from the NCBI data bank under accession numbers M27161 (nucleic acid) and AAA59674(protein).
  • the human sequence of CD8 ⁇ is available from the NCBI data bank under accession numbers M36712 (nucleic acid) and AAA35664 (protein).
  • CD85j The human sequence of CD85j is available from the NCBI data bank under accession numbers BC015731 and NM — 006669 (nucleic acid) and AAH15731 and NP — 006660.1(protein).
  • the anti-CD160 compounds of the invention are anti-angiogenic agents, and are thereby useful for preventing or treating a tumor, such as a carcinoma, or a leukaemia (e.g. B-cell chronic lymphocytic leukaemia).
  • a tumor such as a carcinoma, or a leukaemia (e.g. B-cell chronic lymphocytic leukaemia).
  • a leukaemia e.g. B-cell chronic lymphocytic leukaemia
  • They are also useful for preventing or treating pre-eclampsia or eclampsia, and/or for preventing or treating diabetes, an ischemic ocular disease, or rheumatoid arthritis.
  • An illustrative anti-CD160 compound of the invention comprises said CL1-R2 mAb. From this mAb conservative fragments and derivatives can be produced by the skilled person following routine procedures. Such conservative fragments and derivatives are functional equivalents of said CL1-R2 mAb.
  • an “antibody fragment” is a portion of an antibody such as a heavy chain, a light chain, a VH, a VL, Fab, a Fab′, a F(ab)2, a F(ab′)2, and the like, as well as each minimal recognition units consisting of the amino acid residues that mimic the hypervariable region (CDR1H, CDR2H, CDR3H, CDR1L, CDR2L, CDR3L).
  • Such fragments are obtainable by routine procedures, such as proteolytic digestion (for example, pepsin digestion to generate F(ab′)2 ; papain digestion to generate Fab).
  • Preferred fragments of the invention are those which are conservative, i.e. those CL1-R2 fragments which have retained said desired CD160 binding affinity and specificity (i.e. have retained the feature of binding to CD160 on substantially the same epitope as CL1-R2 and/or capable of competing with CL1-R2 for binding to CD160, and the feature of binding to CD160 without binding to at least one HLA receptor other than CD160, such as e.g. CD8 ⁇ ).
  • Preferred conservative fragment of mAb CL1-R2 comprise Fab, Fab′, F(ab)2, F(ab′)2 or Fv fragments of said mAb CL1-R2.
  • Such conservative fragments may be used as such, for biological and/or medical applications.
  • Non conservative fragments such as a CL1-R2 CDR in isolated form are nevertheless also an object of the present invention, as they can be combined together to form a conservative derivative of CL1-R2.
  • anti-CD160 compounds of the invention also comprise the conservative derivatives of said mAb CL1-R2, i.e. any anti-CD160 compound:
  • the conservative derivative of the invention may be monovalent (one CD160 binding site), or multivalent (at least two CD160 binding sites).
  • Preferred multivalent conservative derivatives include tetravalent conservative derivatives.
  • They e.g. include derivatives which are chimaeric antibodies obtainable by grafting at least one Fv fragment of CL1-R2 to an Fe fragment derived from another antibody.
  • the Fe fragment is preferably chosen to be as less immunoreactive as possible for the organism to which said drug is to be administered.
  • said Fc fragment preferably is a human Fe fragment.
  • Conservative derivatives of the invention also include humanized antibodies, obtainable by grafting at least one CL1-R2 CDR onto a human antibody frame region (hFR). The objective is here also to provide the organism into which said drug is to be administered with a compound that induces as few as undesired immunogenic side effects as possible.
  • Conservative derivatives of the invention also include derivatives obtainable by grafting at least one CL1-R2 VH region to at least one VL region, optionally via a linker (L), such as a peptide linker.
  • L linker
  • Such molecules are known to the skilled person as scFv. They can be monomeric or multimeric.
  • Appropriate linkers are those which allow the VH and VL domains to fold into a single polypeptide chain which has a three dimensional structure very similar to the original structure of the whole antibody, and thus maintain the binding specificity.
  • Such appropriate linkers are known to the skilled person.
  • An illustrative method to produce such linkers is described in WO 88/01649 in the name of GENEX Corp. (U.S. Pat. No. 4,946,778 and U.S. Pat. No. 5,260,203).
  • Said conservative derivative of mAb CL1-R2 may be monovalent, or multivalent.
  • An illustrative conservative derivative of mAb CL1-R2 comprises at least one scFv compound comprising at least one CL1-R2 VH region of CL1-R2 linked to at least one CL1-R2 VL region of CL1-R2 via a peptide linker (L).
  • the scFv can have a VL-L-VH orientation (see e.g. WO 88/01649 in the name of GENEX Corp.—U.S. Pat. No. 4,946,778 and U.S. Pat. No. 5,260,203—), or a VH-L-VL orientation (see e.g. WO 88/09344 in the name of CREATIVE BIOMOLECULES Inc.—U.S. Pat. No. 5,132,405; U.S. Pat. No. 5,091,513; U.S. Pat. No. 5,258,498; U.S. Pat. No. 5,476,786; U.S. Pat. No. 5,482,858;U.S. Pat. No. 6,207,804 B1—).
  • the scFv can be monovalent or multivalent (aggregation of several scFv).
  • Illustrative conservative derivative notably comprises a scFv multimer derived from said CL1-R2 mAb, joined to a Fc fragment.
  • Another illustrative conservative derivative of mAb CL1-R2 is a compound comprising at least one Fv fragment of CL1-R2 linked to a human Fc.
  • Another illustrative conservative derivative of mAb CL1-R2 is obtainable by adding one or more Fab derived from said CL1-R2 mAb at the C-terminus of each H chain of the full length CL1-R2 mAb.
  • Another illustrative conservative derivative of mAb CL1-R2 is obtainable by covalently linking full-length CL1-R2 mAbs together to form an aggregated Ab form.
  • Another illustrative conservative derivative of mAb CL1-R2 is obtainable by linking two or more Fabs head-to-tail.
  • a multivalent scFv according to the present invention is obtainable by linking at least two scFv in a multimer. Linking can be achieved covalently or non-covalently.
  • Illustrative multivalent scFv are tetrameric scFv.
  • Multivalent scFv have more than one binding site. Hence, multimeric scFv having several CD160 binding sites can be produced, to provide an anti-CD160 compound with enhanced avidity for CD160. Such multimeric scFv are particularly advantageous according to the present invention.
  • Multimeric scFv can be monospecific, i.e. all of their binding sites target CD160.
  • multimeric scFv can comprise one or more CD160 binding site(s), as well as one or more other binding site(s) for binding to a target different from CD160.
  • Such other binding site(s) may e.g. target a compound that is different from CD160, but still expressed by EC, so as to direct the action of the compound towards EC more efficiently.
  • Examples of such other target(s) comprise VEGF receptors and all receptors that induce EC growth upon ligation with their physiological ligand.
  • Bi- or multi-specific multimeric scFv are particularly advantageous therapeutic means.
  • Methods to produce multimeric scFv are known to the skilled person, see e.g. WO 94/13806 in the name of The DOW CHEMICAL Company (U.S. Pat. No. 5,877,291 and U.S. Pat. No. 5,892,020), WO 93/11161 in the name of ENZON Inc. (U.S. Pat. No. 6,515,110 B1; U.S. Pat. No. 6,121,424; U.S. Pat. No. 6,027,725;U.S. Pat. No. 5,869,620).
  • the present invention provides a pharmaceutical composition comprising as an active ingredient an anti-CD160 compound of the invention, for use in diagnosis and/or prognosis and/or therapy.
  • composition may be in any pharmaceutical form suitable for administration to a patient, including but not limited to solutions, suspensions, lyophilized powders, capsule and tablets.
  • the pharmaceutical compositions of the invention may further comprise any pharmaceutically acceptable diluent, carrier, excipient or auxiliary.
  • composition of the invention may be formulated for injection, e.g. local injection, transmucosal administration, inhalation, oral administration and more generally any formulation that the skilled person finds appropriate to achieve the desired prognosis and/or diagnosis and/or therapy.
  • the anti-CD160 compound of the invention is contained in said pharmaceutical composition in an amount effective to achieve the intended purpose, and in dosages suitable for the chosen route of administration. More specifically, a therapeutically effective dose means an amount of a compound effective to prevent, alleviate or ameliorate symptoms of the disease or condition of the subject being treated, or to arrest said disease or condition.
  • the anti-CD160 compounds of the invention may further comprise additional constituents.
  • the anti-CD160 compound of the invention when intended for prognosis or diagnosis, it may further comprise a detectable label, such as a fluorochrom, or an entity with enzymatic activity, or with radioactivity, and more generally any entity enabling the detection of said compound.
  • a detectable label such as a fluorochrom, or an entity with enzymatic activity, or with radioactivity, and more generally any entity enabling the detection of said compound.
  • the compound when intended for therapeutic administration to an organism in need thereof, it may further comprise an immunotoxin and/or a radioelement.
  • the anti-CD160 compounds of the invention may of course alternatively be used for the detection of anti-angiogenic sites.
  • the present invention hence also relates to a pharmaceutical composition or kit comprising at least one anti-CD160 compound of the invention, which is intended for the detection of anti-angiogenic sites.
  • the present invention also relates to the use of an anti-CD160 compound of the invention, for the identification of an anti-angiogenic compound.
  • the present invention indeed provides the demonstration that CD160 is expressed by endothelial cells (EC), and that the anti-CD160 compounds of the invention bind to EC-expressed CD160 and thereupon induce an anti-angiogenic effect on said EC.
  • EC endothelial cells
  • the anti-CD160 compounds of the invention have the advantageous ability to act as an activating extracellular ligand of CD160.
  • Equivalents compounds can hence be found by isolation and/or identification of compounds that show equivalent affinity and specificity for binding to CD160, i.e. that have the ability to compete with an anti-CD160 compound of the invention (such as CL1-R2 itself) for binding to CD160, and that are sufficiently CD160-specific for binding to CD160 without binding to at least one HLA receptor other than CD160, such as CD8 ⁇ .
  • an anti-CD160 compound of the invention such as CL1-R2 itself
  • Such an identification and/or isolation can be achieved by e.g. screening method, such as e.g. high throughput screening.
  • the present invention hence also relates to a pharmaceutical composition or a kit comprising at least one anti-CD160 compound of the invention, said pharmaceutical composition or kit being intended for the identification and/or isolation of an anti-angiogenic compound.
  • the present invention thus also relates to the use and more particularly the in vitro use of the anti-CD160 mAb CL1-R2 (obtainable from the hybridoma deposited as CNCM I-3204), or of a conservative fragment thereof, or of a conservative derivative thereof, for the identification and/or isolation of an anti-angiogenic compound, wherein said fragment or derivative is capable of competing with CL1-R2 for binding to CD160, and is sufficiently CD160-specific for binding to CD160 without binding to at least one HLA receptor other than CD160, such as CD8 ⁇ , and wherein said derivative comprises at least one CL1-R2 fragment.
  • the present invention encompasses a method to identify an anti-angiogenic compound, characterized in that it comprises:
  • candidate compound that the skilled person finds appropriate may be provided for implementation of the method of the invention.
  • Illustrative candidate compounds may e.g. be found in chemical or biological collections, such as e.g. viral peptides or peptides deriving from pathogens (for example Cytomegalovirus peptides).
  • the CD160 target to be used for implementation of the methods of the invention may be provided in any form that the skilled person finds appropriate. It may e.g. be provided in the form of a cell expressing CD160 as a functional membrane receptor. Illustrative cells notably comprise EC. EC are obtainable from cell lines such as HUVEC, HMVEC, NK92 (see example 2 below). EC are also obtainable by collection and isolation from a healthy individual.
  • the CD160 target may also be provided in the form of soluble recombinant CD160 proteins (Flag-CD160 or GST-CD160).
  • the present invention also relates to the use, and more particularly the in vitro use of an anti-CD160 compound of the invention as a CD160 activating ligand to identify a CD160 molecular effector or transducer, i.e. the use of an anti-CD160 compound of the invention as a CD160 ligand to identify a molecule which is involved in the anti-angiogenic signal transduction mediated by an EC-expressed CD160.
  • Such effectors and transducers are preferred cell targets for anti-angiogenic drugs, such as anti-tumor drugs.
  • the present invention hence also relates to a pharmaceutical composition or a kit comprising at least one anti-CD160 compound of the invention, said pharmaceutical composition or kit being intended for the identification and/or isolation of lipid-RAFT associated membrane molecule that is involved in CD160 anti-angiogenic signal transduction, and/or of a secondary messenger that is involved in CD160 anti-angiogenic signal transduction.
  • the present invention also relates to a method to identify a lipid RAFT-associated membrane molecule which is involved in CD160 anti-angiogenic signaling pathway when expressed by an endothelial cell, characterized in that it comprises:
  • said at least one CD160-specific compound thus identified is a lipid RAFT-associated membrane molecule that is involved in CD160 anti-angiogenic signaling pathway.
  • any mean and/or method that the skilled person may find appropriate to compare protein patterns can be used.
  • said RAFT fraction may e.g. be placed for migration in a 2-dimension gel (pH/PM), and the protein spots revealed with silver nitrate.
  • Said non-reactive isotype-matched control Ab is a non-relevant Ab which has the same isotype as CL1-R2, but which does not bind to CD160, and does also not bind to any compound that may be found within or on said EC.
  • Said non-reactive isotype-matched control Ab may e.g. be a non-relevant mouse Ig.
  • Said compound which does not bind to CD160 but binds to another EC-expressed receptor may e.g. be an Ab directed to an EC receptor other than CD160, such as an anti-VEGF receptor when EC is used.
  • Illustrative cells notably comprise EC obtainable from cell lines such as HUVEC, HMVEC, NK92 (see example 2 below), or by collection and isolation from a healthy individual.
  • the present invention also relates to a method to identify a secondary messenger which is involved in CD160 anti-angiogenic signal transduction when expressed by an endothelia cell, characterized in that it comprises:
  • said at least one identified compound is a secondary messenger that is involved in CD160 (anti-angiogenic) signal transduction
  • a detectable phosphorus compound (such as radioactive phosphorus provided by e.g. P 32 -ATP, a fluorescent or a luminescent phosphorus compound) is usually used for such in vitro kinase assay.
  • An illustrative experimental procedure is described in Bruyns E, Marie-Cardine A, Kirchgessner H, Sagolla K, Shevchenko A, Mann M, Autschbach F, Bensussan A, Meuer S, Schraven B.
  • TCR ⁇ T cell receptor (TCR) interacting molecule
  • any mean and/or procedure that the skilled person finds appropriate may be used. It may e.g. be proceeded by migration of said fraction of CL1-R2 complex on a polyacrylamide gel, optionally western blotting with anti-phosphoTyr and/or phosphoSer and/or phosphoThr, and detecting incorporated phosphorylation (with a radioactivity scintillation counter when P 32 has been used), recovering the corresponding band (e.g. by elution).
  • Illustrative secondary messengers that are involved in CD160 (anti-angiogenic) signal transduction have been identified by the inventors. They notably comprise pi-3-kinase and lck (p56).
  • Inhibitors of membrane-associated molecules and/or of cytosolic second messenger may have therapeutic applicability. They may advantageously be associated with a compound increasing the specificity of their delivery.
  • the present invention provides the demonstration that cytokine production by NK and T cells uses the CD160 signaling pathway in NK and T cells, and that it can be controlled by aggregated anti-CD160 compounds for up-regulation, or by soluble anti-CD160 compounds or CD160-CD158b cross-linking agents for down-regulation.
  • the present invention provides with anti-CD160 specific compounds that can specifically exert these controls on CD160.
  • the present invention also demonstrates that cross-linking CD160 to CD158b induces an inhibition of CD160 activation, thereby resulting in an inhibition of the cytokine production.
  • the cytokine profile that is induced by stimulation of CD160 is unique compared to the one obtained by stimulation of other NK-expressed receptors such as CD 16 or NKG2D.
  • the CD160-triggered cytokine profile is unique also in the sense that it very closely mimics the one obtained by stimulation with the natural CD160 ligand (sHLA).
  • Stimulation of CD160 induces the production and secretion of IFN ⁇ , TNF ⁇ and IL-6. Except for the natural ligand sHLA, it is the first that time that there is provided a ligand that induces IL-6 production from NK cells.
  • the CD160 ligands provided by the present invention are anti-CD160 specific compounds. They notably comprise the anti-CD160 monoclonal antibody referred to by the inventors as CL1-R2.
  • CL1-R2 producing hybridoma has been deposited within the Collection Nationale de Cultures de Microorganismes in accordance with the Budapest Treaty under CNCM deposit accession number I-3204 (C.N.C.M. Institut Pasteur 25, rue du Dondel Roux F-75724 Paris Cedex 15 France).
  • CD160 is expressed by CD4+ T cells.
  • CD160 detections could and can be made because the present invention provides a publicly-available anti-CD160 specific compound.
  • CD160+ CD4+ cells have notably been identified within a skin sample from a human patient suffering from atopic dermatitis.
  • anti-CD160 compounds of the invention which are useful for regulating NK and T cells cytokine production are identical to those which have been above-described for EC and angiogenesis: they comprise the mAb CL1-R2 of the invention as well as the conservative fragments and derivatives thereof.
  • the structural description, the affinity and specificity properties that have been described for the anti-CD160 compounds of the invention in the context of EC angiogenesis hence apply mutatis mutandis to the anti-CD160 compounds of the invention in the context of regulation of NK and T cell cytokine production.
  • HLA receptors other than CD160 such as CD8 ⁇ and/or CD85j and/or CD4 is not advantageous, as such compounds would induce uncontrolled chain reaction in the organism to which they would be administered. They would notably induce T cell apoptosis if they were comprising an anti-CD8 ligand.
  • anti-CD160 compounds of the invention when used as ligands of CD160 expressed as an immune receptor on NK and/or T cells, and the anti-CD160 compounds of the invention when used as ligands of CD160 expressed as an endothelial cell receptor.
  • the soluble anti-CD160 compounds of the invention induce an inhibition of CD160 signalling pathway (i.e. inhibition of cytokine production), whereas the aggregated forms of the anti-CD160 compounds of the invention induces a CD160 stimulation (i.e. induction of, or stimulation of cytokine production).
  • the present invention hence also relates to anti-CD160 compounds which comprise with the anti-CD160 mAb CL1-R2 (obtainable from the hybridoma deposited as CNCM I-3204), and any compound which is capable of competing with CL1-R2 for binding to CD160, and which is sufficiently CD160-specific for binding to CD160 without binding to at least one HLA receptor other than CD160, such as and preferably CD8 ⁇ .
  • CL1-R2 obtainable from the hybridoma deposited as CNCM I-3204
  • any compound which is capable of competing with CL1-R2 for binding to CD160 and which is sufficiently CD160-specific for binding to CD160 without binding to at least one HLA receptor other than CD160, such as and preferably CD8 ⁇ .
  • the anti-CD160 compounds of the invention do further not bind to CD85j and/or CD4.
  • the anti-CD160 compounds of the invention do not bind to any HLA receptor other than CD160.
  • the present invention also relates to a pharmaceutical composition, such as a drug, comprising an anti-CD160 compound of the invention.
  • Such a drug is useful for inducing or inhibiting, and/or up- or down-regulating the cytokine production of an individual.
  • Said cytokines notably comprise IFN ⁇ and/or TNF ⁇ and/or IL-6.
  • Such a drug is useful for the (curing and/or preventing and/or palliative) treatment of any disease or condition involving an excessive or an insufficient cytokine production.
  • Such a drug can thus be useful for inducing or inhibiting, and/or up- or down-regulating the adaptive immunity potential of said individual. It thus enables the regulation of a Th1 response.
  • Said drug may also be intended for the treatment or prevention of an infection.
  • Said drug may also be intended as an additional product, such as an adjuvant, in a vaccine procedure to induce and/or amplify specific cytotoxic T lymphocyte (CTL) responses.
  • CTL cytotoxic T lymphocyte
  • Said drug may also be intended for inducing or inhibiting, and/or up- or down-regulating hematopoiesis in an individual, for the (curing or palliative or preventive) treatment of irradiated individuals and/or for the treatment or prevention of bone marrow aplasia.
  • a drug would then be very useful to patients that have been submitted to irradiation in a pre-graft treatment or as an anti-tumor treatment: the anti-CD160 compounds of the invention can indeed help them in restoring their blood cell population.
  • Said drug may also be intended for inducing or inhibiting, and/or up- or down-regulating an inflammatory reaction in said individual, and/or for the treatment or prevention of an allergy in said individual, such as atopic dermatitis.
  • Said drug may also be intended to induce a vasodilatation.
  • an anti-CD160 compound of the invention may comprise at least one CD158b binding site in addition to its CD160 binding site(s). Cross-linking of CD160 and CD158b indeed induces an inhibition of CD160 signaling pathway.
  • the anti-CD160 of the invention may be provided in soluble form.
  • the anti-CD160 compounds of the invention indeed inhibit CD160 signaling pathway.
  • soluble form it is herein meant a “soluble” form as intended by the skilled person in the field of immune system receptor-ligand interactions. More particularly, the fact that a ligand is in soluble form implies that said ligand has one or two, but no more than two, binding site(s) for the activating target, i.e. in the present for CD160.
  • a ligand is in aggregated form implies that said ligand has at least two binding sites for the activating target, i.e. in the present for CD160.
  • the anti-CD160 compounds of the invention in soluble form comprise the anti-CD160 mAb obtainable from hybridoma CNCM I-3204 (IgG).
  • CL1-R2 also comprise the conservative fragments of CL1-R2, i.e. the CL1-R2 fragments that have retained an affinity for binding to CD160, and more particularly the ability to compete with CL1-R2 for binding to CD160, and that have retained a sufficient CD160-specificity for binding to CD160, without binding to at least CD8 ⁇ .
  • conservative fragments notably comprise the Fab, Fab′, F(ab)2, F(ab′)2 and Fv fragments of said mAb CL1-R2.
  • anti-CD160 compounds of the invention in soluble form also comprise mono- or divalent conservative derivatives of CL1-R2, i.e. a compound:
  • Illustrative mono- or divalent conservative derivatives of CL1-R2 comprise:
  • the anti-CD160 compounds of the invention may be provided in an aggregated form, i.e. as a compound comprising at least three CD160 binding sites and no CD158b binding site.
  • Such aggregated forms of the anti-CD160 compounds of the invention are obtainable by aggregation of the soluble forms of the anti-CD160 compounds of the invention. Aggregated forms can be obtained by genetic manipulation or chemically with linkers.
  • the present invention also relates to the use of the anti-CD160 mAb CL1-R2.(obtainable from the hybridoma TM60 deposited as CNCM I-3204), or of a conservative fragment thereof, or of a conservative derivative thereof, for the identification and/or isolation of a compound having the ability to induce or inhibit, and/or to up- or down-regulate the cytokine production of a NK and/or a T CD8+ and/or a T CD4+ cell,
  • said fragment or derivative is capable of competing with CL1-R2 for binding to CD160, and is sufficiently CD160-specific for binding to CD160 without binding to at least CD8 ⁇ , and
  • said derivative comprises at least one CL1-R2 fragment.
  • the present invention encompasses a method to identify a compound having the ability to induce or inhibit, and/or to down- or up-regulate the cytokine production of a NK cell and/or a T CD8+ cell and/or a T CD4+ cell, characterized in that it comprises:
  • the present invention also encompasses the use of the anti-CD160 mAb CL1-R2 (obtainable from the hybridoma deposited as CNCM I-3204), or of a conservative fragment thereof, or of a conservative derivative thereof, as a CD160 ligand to identify a molecule which is involved in the CD160-mediated cytokine production of a NK cell and/or a T CD8+ cell and/or a T CD4+ cell,
  • said fragment or derivative is capable of competing with CL1-R2 for binding to CD160, and is sufficiently CD160-specific for binding to CD160 without binding to at least CD8 ⁇ , and
  • said derivative comprises at least one CL1-R2 fragment.
  • the present invention relates to a method to identify a molecule which is involved in the CD160-mediated cytokine production of a NK cell and/or a T CD8+ cell and/or a T CD4+ cell, and which is expressed by said cell as a lipid RAPT-associated membrane molecule, characterized in that it comprises:
  • said at least one CD160-specific compound thus identified is a molecule which is involved in the CD160-mediated cytokine production of said cell, and which is expressed by said cell as a lipid RAFT-associated membrane molecule.
  • the anti-CD160 compounds of the invention also allows for the identification of those molecules which are expressed in the cytolic compartment of an NK cell and which are involved in the CD160 signal transduction, thereby mediated an up- or down-regulation of the cytokine production of said NK cell.
  • the present invention hence also relates to a method to identify a secondary messenger which is involved in the CD160-mediated cytokine production of a NK cell and/or a T CD8+ cell and/or a T CD4+ cell, characterized in that it comprises:
  • said at least one identified compound is a secondary messenger which is involved in the CD160-mediated cytokine production of said cell
  • in vitro kinase assay are well-known to the skilled person.
  • a detectable phosphorus compound such as radioactive phosphorus provided by e.g. P 32 -ATP, a fluorescent or a luminescent phosphorus compound
  • P 32 -ATP a detectable phosphorus compound
  • fluorescent or a luminescent phosphorus compound is usually used for such in vitro kinase assay.
  • TCR T cell receptor
  • TCR-CD3-zeta complex ⁇ T cell receptor (TCR) interacting molecule (TRIM), a novel disulfide-linked dimer associated with the TCR-CD3-zeta complex, recruits intracellular signalling proteins to the plasma membrane>> J Exp Med. 1998 Aug. 3;188(3):561-75.
  • Illustrative secondary messengers that are involved in CD160 (anti-angiogenic) signal transduction have been identified by the inventors. They notably comprise pi-3-kinase and lck (p56).
  • the present invention also relates to:
  • the present invention also encompasses the use of an anti-CD160 compound of the invention to induce CTL differentiation.
  • FIGS. 1A , 1 B, 1 C HLA-C triggers cytokine production by NK92 and PB-NK cells.
  • FIG. 1A IL-2 treated NK92 cells were co-cultured for 4 h with K562 Class-I+ in the absence or presence of blocking concentrations of W6/32 anti-HLA-C mAb (lower panel). Cells were fixed, permeabilized, and stained for intracellular TNF- ⁇ expression, as described in Materials and Methods. K562 Class-I+ or NK92 cells alone were used as controls (upper panel).
  • K562 Class-I+ , K562, and K562-Cw5 were analyzed by flow cytometry for surface expression of HLA-C using W6/32 mAb, followed by PE-conjugate (open profiles). Dark profiles are Ig-isotype control staining.
  • FIG. 1C Simultaneous measurement of IL-4, IL-6, IL-10, TNF- ⁇ and IFN- ⁇ production by PB-NK after 16 h of culture alone or co-culture with K562 Class-I+ , K562 or K562-Cw5.
  • FIG. 2 CD160 mAb cross-linking triggers TNF- ⁇ , IFN- ⁇ and IL-6 cytokine production by PB-NK cells.
  • sample supernatants were analyzed by CBA for cytokine production, as described in Materials and Methods. Cytokine concentrations in the samples were calculated relative to the appropriate calibration curves with standard dilutions for each cytokine. Results are expressed as mean ⁇ SE of nine independent experiments performed with different donors. *P ⁇ 0.05, **P ⁇ 0.03, ***P ⁇ 0.01, ****P ⁇ 0.003, *****P ⁇ 0.008 (Student T-test).
  • FIGS. 3A and 3B Inhibition of CD160-mediated TNF- ⁇ , IFN- ⁇ and IL-6 cytokine production by the CD158b inhibitory receptor.
  • FIG. 3A Freshly purified PB-NK were immediately analyzed by flow cytometry for surface expression of CD160, CD56, CD3, CD16, CD158b, and NKG2D using PE-Cy5-conjugated BY55 anti-CD160 mAb and/or PE-conjugated anti-CD56, -CD3, -CD16, -CD158b mAbs and/or anti-NKG2D mAb, followed by PE-conjugated F(ab′) 2 goat anti-mouse IgG1 Ab.
  • Upper panel single staining (dark profiles); open profiles are PE-Cy5-IgM or PE-IgG isotype control staining.
  • Lower panel double staining: the percentage of cells positive for both CD160 and another marker is indicated. Results are representative of five different experiments.
  • CD160, NKG2D, and CD158b NK cell receptors were cross-linked alone or co-cross-linked on PB-NK cells with specific mAbs using the appropriate concentrations, as described in Materials and Methods. Following 16 h receptor activation, sample supernatants were analyzed by CBA, as described in Materials and Methods. Data are taken from one representative experiment out of five performed with different donors.
  • FIGS. 4A , 4 B, 4 C, 4 D Effect of sHLA-G1 on VEGF or FGF2-induced EC proliferation, migration and capillary-like tube formation.
  • FIG. 4A Inhibition of VEGF-mediated HUVEC proliferation by sHLA-G1.
  • Cells were seeded at low density in the presence of VEGF and incubated with varying concentrations of sHLA-G1 (sG1) or control sHLA-G1- ⁇ 2m monochain (sG1mono). After 7 days of culture, cells were trypsinized and counted.
  • sG1 sHLA-G1
  • sG1mono control sHLA-G1- ⁇ 2m monochain
  • FIG. 4B Inhibition of VEGF-induced HUVEC migration by sG1 or sG1mono.
  • Growth arrested HUVEC monolayers were scrapped and were either not stimulated ( ⁇ ) or stimulated with VEGF, in the absence ( ⁇ ) or in the presence of sG1 or sG1mono. 18 h later cell monolayers were stained with May-Grunwald Giernsa and the migration of cells was counted as indicated in Mat. and Methods.
  • FIGS. 4C and 4D Inhibition of FGF-2-induced HUVEC in vitro angiogenesis by sHLA-G1.
  • HUVEC were seeded on Matrigel diluted in collagen gel in the presence or absence of FGF-2 and/or sG1. 24 h later, photographs of each well was taken ( FIG. 4C ), and angiogenesis was quantified as described in Materials and Methods ( FIG. 4D ). Photomicrographs of representative wells show the decreased FGF-2-induced HUVEC tube formation after sHLA-G1 incubation, in comparison with FGF-2 alone or FGF-2 and control.
  • the control for sHLA-G1 is culture supernatant from untransfected cells, passed through immunoaffinity column, eluted and pooled (10).
  • Results in A, B and D are means ⁇ SD of triplicate wells and are representative of five independent experiments.
  • FIGS. 5A , 5 B sHLA-G1 does not bind to VEGF receptors.
  • FIG. 5A HUVEC were incubated with 125 I-sHLA-G1 in the absence ( ⁇ ) or presence of cold VEGF, FGF-2 or varying concentrations of sHLA-G1 (sG1). Unlabeled sHLA-G1 but not VEGF nor FGF-2 prevented 125 I-sHLA-G1 binding.
  • FIG. 5B HUVEC were incubated with iodinated VEGF in the presence of cold sG1, FGF-2 or VEGF. Unlike cold VEGF, cold sG1 did not abrogate iodinated VEGF binding. Results are means ⁇ SD of triplicate wells and are representative of 5 independent experiments.
  • FIGS. 6A , 6 B, 6 C sHLA-G1 binds to the CD160 receptor expressed by EC.
  • FIG. 6A HUVEC were analyzed by flow cytometry after incubation with CD8, ILT2 or CL1-R2 (CD160) specific mAbs (open profiles) or Ig-isotype control Ab (black profiles) followed by FITC-labeled conjugates, in the presence or not of VEGF or sG1. Results are representative of six independent experiments.
  • FIG. 6B CD160 mRNA expression in NK92, HUVEC and PB-CD4+ lymphocytes was measured by RT-PCR, using CD160 (top) or ⁇ -actin (bottom) primers.
  • FIG. 6C Predicted amino acid sequence alignment of CD160 expressed in NK92 (NK) and HUVEC.
  • FIGS. 7A , 7 B HLA-G tetramers bind to Jurkat-CD 160 and HUVEC.
  • FIG. 7A By flow cytometry, mAb CL1-R2 stained Jurkat-CD160 but not untransfected Jurkat (open profiles). Black profiles are Ig-isotype control stainings.
  • HLA-G1 tetramer cross-linked with W6/32 mAb followed by incubation with streptavidin-PE, binds to Jurkat-CD160 but not to untransfected Jurkat, whereas not-cross-linked HLA-G1 tetramer, followed by incubation with streptavidin-PE, binds to HUVEC (open profiles). Black profiles are control staining with streptavidin-PE.
  • HUVEC were incubated or not with sHLA-G1 (100 ng/ml) at 4° C. After 2 h, cells were incubated with CL1-R2 mAb followed by PE-conjugate and analyzed by flow cytometry (open profiles). Black profile is Ig-isotype control staining. Results are representative of 3 independent experiments.
  • FIG. 8 mAb cross-linking of CD160 triggers inhibition of in vitro angiogenesis.
  • HUVEC were seeded on Matrigel diluted in collagen gel in the presence or absence of FGF-2 and sHLA6G1 and/or mAb CD160 or Ig-isotype control. 24 h later, photography of each well was taken and angiogenesis quantified as described in Materials and Methods. Results are mean+/6 SD of triplicate wells and are representative of 5 independent experiments.
  • FIGS. 9A , 9 B Effect of hypoxia on EC CD160 expression.
  • HUVEC were incubated in normoxia or hypoxia (5% 02) conditions during 24 h and analyzed for surface expression of CD160 using CL1-R2 mAb ( FIG. 9A ), or VCMAM, using anti-CD106 mAb ( FIG. 9B ), followed by PE-labeled conjugate. Black profiles are Ig-isotype control stainings. Results are representative of 3 independent experiments.
  • FIGS. 10A , 10 B, 10 C, 10 D CL1-R2 mAb immunohistochemistry on tumor sections, showing that CD160 is not expressed by tumor cells, but is expressed at a high level by EC of lymphatic vessels at the periphery of the tumor and EC of microvessels inside the tumor.
  • FIGS. 10A and 10B CD160 staining of lymphatic microvessels at the periphery of the tumor.
  • FIGS. 10C and 10D CD160 staining of microvessels inside the tumor.
  • FIG. 11 Induction of CD160 transcripts in CD4+ lymphocytes with IL-15.
  • FIG. 12 a, 12 b, 12 c, 12 d sHLA-G1 inhibits VEGF- or FGF2-mediated endothelial cell proliferation, migration and capillary-like tube formation.
  • sG1 sG1
  • sG1mono sHLA-G1
  • sHLA-G1 induces apoptosis of endothelial cells.
  • FIG. 2 Images of endothelial cells after treatment with sG1 or neo conditioned media (Supplementary FIG. 2 video clip online).
  • the area under the curve was calculated from the kinetics curves shown in (c). **P ⁇ 0.003 Mann Whitney U test.
  • FIG. 14 a, 14 b sHLA-G1 does not interfere with VEGF receptors.
  • HUVEC were incubated with 125 I-sHLA-G1 in the absence ( ⁇ ) or presence of cold VEGF, FGF-2 or varying concentrations of sHLA-G1 (sG1). Unlabeled sHLA-G1 but not VEGF nor FGF-2 prevented 125 I-sHLA-G1 binding.
  • HUVEC were incubated with 125 I-VEGF in the presence of cold sG1, FGF-2 or VEGF. Unlike cold VEGF, cold sG1 did not abrogate iodinated VEGF binding. Results are means ⁇ SEM of triplicate wells and are representative of three independent experiments.
  • FIG. 15 a, 15 b, 15 c HUVEC express the CD160 receptor.
  • HUVEC and HMVEC were analyzed by flow cytometry after incubation with CD8, CD85d, CD85j or CL1-R2 (CD160) specific mAbs (open profiles) or Ig isotype controls (black profiles) followed by FITC-labeled conjugates. Results are representative of six independent experiments.
  • c Predicted amino acid sequence alignment of CD160 expressed in HUVEC and NK92.
  • ⁇ indicates identity.
  • FIG. 16 a, 16 b, 16 c, 16 d Immunohistochemical staining of Lewis lung carcinoma tumor sections with anti-CD160 mAb demonstrating CD160 positive vessels in brown. Vessel network staining was localized at the periphery of the tumor (a). Blood vessels in the periphery (b) and the centre of the tumor (c,d) were also stained with CD160 mAb, whereas tumor cells remained unstained. Magnification, ⁇ 400.
  • FIG. 17 a, 17 b, 17 c, 17 d sHLA-G1 binds to the CD160 receptor expressed by endothelial cells.
  • (a, lower), HLA-G1 tetramer binds to HUVEC and Jurkat-CD160 control transfectant but not to untransfected Jurkat cells (black profiles, control staining with streptavidin-PE).
  • Recombinant sHLA-G1 blocks CD160 mAb binding to HUVEC (black profile, isotype control). Results are representative of three independent experiments.
  • Soluble CL1-R2 anti-CD160 mAb triggers inhibition of in vitro angiogenesis.
  • HUVEC were seeded on Matrigel in the presence or absence of FGF-2 and sHLA-G1 and/or mAb CD160 (+++, 10 ⁇ g/ml; +, 1 ⁇ g/ml) or IgG1-isotype control (10 ⁇ g/ml).
  • Photographs of each well were taken after 24 h and angiogenesis quantified. Results are mean ⁇ SD of triplicate wells and are representative of five independent experiments. ***P ⁇ 0.001, *P ⁇ 0.005 by ANOVA test, compared to FGF-2-treated cells.
  • Soluble CL1-R2 anti-CD160 mAb induces endothelial apoptosis.
  • SGHEC-7 cells were incubated with CL1-R2 (+, 1 ⁇ g/ml, ++, 5 ⁇ g/ml, +++, 10 ⁇ g/ml) or IgG1 isotype control (10 ⁇ g/ml) and time lapse microscopy was carried out to assess the appearance of apoptotic morphology. Levels of apoptosis after 50 h are shown with mean ⁇ SD of pooled data from 3 experiments. *P ⁇ 0.05, **P ⁇ 0.01, ***P ⁇ 0.001 by ANOVA test, compared to control.
  • FIG. 18 a Expression of CD160 on HUVEC and HMVEC as compared to negative control cells (Smooth muscle cells and human fibroblast in primary culture). Flow cytometry analysis using BY55 anti-CD160 mAb (IgM) as compared to IgM isotype control. Cells were incubated with either of these antibodies, washed and incubated with an anti-IgM-FITC conjugate.
  • IgM BY55 anti-CD160 mAb
  • FIG. 18 b CL-R2 mAb induces apoptosis of HUVEC but not of fibroblast (Assessment by annexin-V and PI double-staining flow cytometry)
  • FIG. 18 c Same method as in FIG. 18 b. Mean of 2 different experiments (5 different wells for each experiment)
  • Effector cells were the human CD160 + NK92 line (ATCC Number CRL-2407) cultured with IL-2 for several days, and fresh human peripheral blood (PB)-NK cells derived from normal donors, purified by immunomagnetic NK cell isolation kit (Miltenyi Biotec). PB-NK purity was shown to be >90% CD3 ⁇ CD56 + by flow cytometry and >90% of purified PB-NK were CD160 + .
  • K562 erythroleukemia cells Two variants of human K562 erythroleukemia cells were used as target cells: one variant (K562 class I+ ) expressed HLA-C when cultured with IFN- ⁇ (publication under reference 14; ATCC CCL-243) whereas the other (K562 cultured with IFN- ⁇ , ATCC CCL-243) did not K562-HLA-Cw5 transfectants (K562-Cw5) were obtained by transfection of HLA-Cw5 cDNA in K562 MHC class I negative parental cells.
  • cells were incubated with PE-Cy5-conjugated BY55, followed by PE-conjugated anti-CD56, -CD3, -CD16, -CD158b mAbs, or by anti-NKG2D mAb followed by PE-conjugated F(ab′) 2 goat anti-mouse IgG1 Ab.
  • PE-Cy5-IgM or PE-IgG were used as isotype controls. Samples were analyzed on an EPICS XL4C flow cytometer (Beckman-Coulter).
  • Receptor specific mAb-mediated cross-linking Cross-linking of CD160, NKG2D, CD16, or CD158b receptors on PB-NK cells was performed in the final concentration of 1-10 ⁇ g/ml during 16 h incubation at 37° C. in 5% CO 2 . IgG1 isotype control was also used at the same conditions. 100 U/ml IL-2 was added during the incubation time. Supernatants were collected and stored at ⁇ 80° C. until further analysis.
  • NK92 or PB-NK cells were incubated alone or co-incubated either with K562 class I+ , K562 or K562-Cw5 at a ratio of 10:1 during 4 h (NK92) or 16 h (PB-NK) at 37° C. in the presence or not of blocking concentrations (25-50 ⁇ g/ml) of W6/32 or CL1-R2 mAbs or Ig-isotype controls. 100 U/ml IL-2 was added during the incubation times.
  • NK92 cells treated as above were washed, fixed in 2% paraformaldehyde, permeabilized with 0.1% saponin for 10 min, stained by PE-conjugated anti-TNF- ⁇ mAb or mouse IgG1-PE (Coulter-Immunotech) and analyzed by an EPICS XL4C flow cytometer (Coulter).
  • Cytokine measurement by Cytometric Bead Array The Th1/Th2 Cytometric Bead Array (CBA) kit (BD Biosciences) was used for simultaneous measurement of IL-2, IL4, IL-6, IL-10, TNF- ⁇ and IFN- ⁇ according to the manufacturer's instructions (Cook, E. B., J. L. Stahl, L. Lowe, R. Chen, E. Morgan, J. Wilson, R. Varro, A. Chan, F. M. Graziano, and N. P. Barney. 2001. Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based flow cytometry: allergies vs. non-allergics. J. Immunol. Meth.
  • CBA uses a series of uniform-size beads with discrete fluorescence intensity (FL3). Each series of beads is coated with a mAb against a single cytokine (IL-2, IL-4, IL-6, IL-10, TNF- ⁇ or IFN- ⁇ and the mixture of beads detects six cytokines in one sample.
  • a cytokine standard containing a mixture of predetermined amounts of all six cytokines was used to prepare standard curves.10 ⁇ l aliquot of each capture bead specific for IL-2, IL-4, IL-6, IL-10, TNF- ⁇ and IFN- ⁇ was mixed for each assay tube to be analyzed.
  • TNF- ⁇ production could be obtained in the NK92 cell line which expresses high amount of CD160. Intracellular expression of this cytokine was evaluated by flow cytometry in NK92 co-cultured with HLA-C expressing K562 (K562 class I+ ) target cells. We found that such co-culture stimulated TNF- ⁇ production, as compared with the moderate secretion of this cytokine by NK92 cultured alone ( FIG. 1A ). Absence of TNF- ⁇ production by K 562 class I+ alone indicated that TNF- ⁇ release was produced solely by NK92.
  • PB-NK were co-cultured for 16 h either with K562 class I+ , K562-Cw5 transfectant, which both express HLA-C molecules at their cell surface, or with K562 which is entirely MHC class I negative ( FIG. 1B ).
  • TNF- ⁇ and four other Th1/Th2 cytokines were measured in the cell-free supernatant fluid ( FIG. 1C for one representative experiment and Table I for 5 independent experiments).
  • PB-NK were co-cultured with K562 class I+ in the presence of blocking concentrations of mAbs to either CD160 or HLA-C, or of Ig-isotype controls (Table II).
  • Anti-CD160 and -HLA-C blocking mAbs prevent production of IFN- ⁇ , TNF- ⁇ and IL-6 by PB-NK co-cultured with K562 Class-I+ IFN- ⁇ TNF- ⁇ IL-4 IL-6 IL-10 Type (pg/m (pg/m (pg/m (pg/m (pg/m (pg/m (pg/m NK 186 ⁇ 18 ⁇ 0 20 ⁇ 0 NK/K562 Class-I+ + 23,054 ⁇ 200 ⁇ 0 414 ⁇ 0 IgG1 NK/K562 Class-I+ + 1,083 a ⁇ 58 c ⁇ 0 143 b ⁇ 0 anti-CD160 mAb NK/K562 Class-I+ + 16,125 ⁇ 215 ⁇ 0 478 ⁇ 0 IgG2a NK/K562 Class-I+ + 1,149 c ⁇ 64 c ⁇ 0 370 ⁇ 0 anti-HLA-C mAb Purified
  • HLA-C ligand or CD160 receptor by their specific mAbs significantly diminished the IFN- ⁇ , TNF- ⁇ and IL-6 production. These results show that this PB-NK cytokine production is mainly attributable to CD160-HLA-C interaction. However, for an unknown reason, the use of W6/32 anti-HLA-C mAb did not significantly inhibit IL-6 secretion.
  • NCR natural cytotoxic receptors
  • 2B4/CD244 co-receptor were excluded from this comparison as they are equally distributed on both cytotoxic and non-cytotoxic PB-NK lymphocytes (Ferlazzo, G., and C. Münz. 2004. NK cell compartments and their activation by dendritic cells. J. Immunol. 172:1333-1339.).
  • NKG2D activating receptor triggering was used as negative control for its inability to mediate cytokine production by itself in human NK cells (André, P., R. Castriconi, M.
  • CD160-mAb cross-linking leads PB-NK to produce the same pattern of cytokine release, namely high levels of IFN- ⁇ , and lower amounts of TNF- ⁇ and IL-6, but no IL-4 nor IL-10 ( FIG. 2 ), than the HLA-C physiological ligand triggering (Table 1).
  • the use of an isotype-matched control Ig did not lead to such secretion.
  • IL-6 is a multifunctional cytokine that acts in the immune system and a recent report has shown that some tumor-infiltrating lymphocytes produced high concentrations of IL-6, blocking the anti-LAK activity of tumor cell TGF- ⁇ 1 (Hsiao, Y. W., K. W. Liao, S. W. Hung, and R. M. Chu. 2004. Tumor-Infiltrating Lymphocyte Secretion of IL-6 Antagonizes Tumor-Derived TGF-beta1 and Restores the Lymphokine-Activated Killing Activity. J. Immunol. 172:1508-1514.).
  • Activation of NK cells is dependent on activating receptors that are normally functionally silenced by inhibitory receptors, including the killer immunoglobulin-like receptors (KIRs) that recognize different allelic groups of HLA-A, -B or -C molecules.
  • KIRs killer immunoglobulin-like receptors
  • FIG. 3A shows the results obtained with one representative donor.
  • PB-NK A major subset of PB-NK expresses CD160, whereas all of them are CD56 + , CD3 ⁇ , and CD16 + ( FIG. 3A , upper panel). Whereas the whole PB-NK population is NKG2D + , only a subset expresses CD158b inhibitory receptor. Double staining confirms that CD160 + PB-NK were CD3 ⁇ , and mostly CD56 dim and CD16 + (FIG. 3A, lower panel). In addition, we found that only subpopulations of CD160 + cells also expressed CD158b or NKG2D ( FIG. 3A , lower panel).
  • CD160 receptor whose expression is restricted to the effector cytotoxic CD56 dim CD 16 bright PB-NK cell subset, appears as a unique MHC class I-dependent activating receptor capable to promote cytokine secretion upon specific ligation.
  • HLA-C major ligand of CD160 is constitutively expressed, which differs from the inducible self-ligands or pathogens induced ligands of the other NK triggering receptors expressed on both cytotoxic and non-cytotoxic NK lymphocyte subsets.
  • Human NKG2D ligands are the stress-induced MICA and MICB molecules that are expressed predominantly by cells of epithelial origin or pathogen encoded ULBP (Raulet, D. H. 2003.
  • NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. 3:781-790.
  • NKG2D is unable to trigger by itself IFN- ⁇ production in human (Carayannopoulos, L., and W. Yokoyama 2004. Recognition of infected cells by natural killer cells. Curr. Opin. Immunol. 16:26-33.).
  • Poliovirus receptor (CD155) and Nectin-2 (CD112) ligands of the DNAM-1 co-activating receptor are also mostly expressed in stressed tissues (Moretta, L., and A. Moretta 2004. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. Embo J. 23:255-259.).
  • NCR ligands are non-MHC molecules, including SV hemaglutinin-neuraminidase for NKp44 and NKp46 (Carayannopoulos, L., and W. Yokoyama. 2004. Recognition of infected cells by natural killer cells. Curr. Opin. Immunol. 16:26-33.).
  • CD16 is present only on effector cytotoxic PB-NK lymphocyte subset and its ligand is the Fc portion of IgG.
  • stimulatory KIRs and CD94/NKG2C activating receptor that are only expressed by a subset of cytotoxic PB-NK lymphocytes, also interact with constitutive HLA class I molecules, including HLA-C for the former, have short cytoplasmic domains with no known signaling motif (Cerwenka, A., and L. Lanier. 2001. Natural Killer cells, viruses and cancer. Nat. Rev. Immunol. 1:41-49.).
  • these activating receptors associate with adaptor molecules to initiate signaling (Lanier, L. 2003. Natural killer cell receptor signaling. Curr. Opin. Immunol. 15:308-314.), which differs from CD160 GPI-anchored cell surface molecule (Le Bouteiller, P., A.
  • NK natural killer
  • 2B4/CD244 is an NK cell receptor that provides a co-stimulatory signal to other activation receptors including NCR or NKG2D (Moretta, L., M. Mingari, C. Bottino, D. Pende, R. Biassoni, and A. Moretta 2003. Cellular and molecular basis of natural killer and natural killer-like activity. Immunol. Letters 88:89-93.).
  • the signals that transform a circulating resting NK cell into an activated cytokine-secreting cell in vivo are not fully understood. This mainly depends on the outcome of signals derived from activating and inhibitory receptors upon engagement by their specific ligands. Knowing that CD158a/CD158b inhibitory receptors engage HLA-C molecules on target cells, we hypothesize that the level of expression of HLA-C may be a key factor to trigger either the KIR or CD160 receptors. When the level of HLA-C is normal, KIR inhibitor receptor engagement would control CD160. In contrast, when the level of expression of HLA-C is down modulated, KIR receptors might no longer be efficiently engaged, allowing the activating function of CD160 receptor to take place.
  • HMVEC human microvascular endothelial cells
  • EBM BioWhittaker
  • FCS 5% FCS
  • FGF-2 R & D systems, Minneapolis, Ill.
  • Jurkat cells transfected with CD160 were produced by transfection of CD160 in Jurkat cells as reported by Anumantha, A., A. Bensussan, L. Boumsell, A. Christ, R. Blumberg, S. Voss, A. Patel, M. Robertson, L. Nadler, and G. Freeman, 1998 (“Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes”, Journal of Immunology 161:2780.)
  • NK92 is a Human NK Cell Line Expressing CD160 (ATCC Number CRL-2407).
  • CD4 + T cells were purified from PBMC using the MACS separation system (Miltenyi Biotec, Auburn, Calif.).
  • the sHLA-G1- ⁇ 2m fusion monochain gene was engineered by connecting the last residue of the ⁇ 3 domain of HLA-G to the first codon of the human ⁇ 2m sequence through a 15-residue spacer (Fournel, S., M. Aguerre-Girr, A. Campan, L. Salauze, A. Berrebi, Y. Lone, F. Lieri, and P. Le Bouteiller. 1999. Soluble HLA-G: purification from eucaryotic transfected cells and detection by a specific ELISA.
  • sHLA-G1 and sHLA-G1mono were purified from eucaryotic cell culture supernatants, using immunoaffinity columns, as previously described (Fournel, S., M. Aguerre-Girr, A. Campan, L. Salauze, A. Berrebi, Y. Lone, F. Lenfant, and P. Le Bouteiller. 1999. Soluble HLA-G: purification from eucaryotic transfected cells and detection by a specific ELISA. American Journal of Reproductive Immunology 42:22.).
  • VEGF 165 was expressed in a baculovirus system as described (Plou ⁇ t J., F. Moro, S.
  • HLA-G tetramers were produced essentially as previously described (Allan, D. S., M. Colonna, L. L. Lanier, T. D. Churakova, J. S. Abrams, S. A. Ellis, A. J. McMichael, and V. M. Braud. 1999. Tetrameric complexes of human histocompatibility leukocyte antigen (HLA)-G bind to peripheral blood myelomonocytic cells. J Exp Med 189:1149.), using synthetic self-peptide RIIPRHLQL (SEQ ID NO:7) and after addition of streptavidin-PE (Pharmingen) (Lee, N., A. R. Malacko, A. Ishitani, M.
  • HLA-G bind identical sets of endogenous peptides but differ with respect to TAP association. Immunity 3:591). Labeling of HUVEC, Jurkat and Jurkat-CD160 by PE-conjugated HLA-G tetramers was performed at 37° C. for 1 h. For Jurkat-CD160 and Jurkat, tetramers were cross-linked with anti-class HLA class I W6/32 mAb.
  • Lewis lung carcinoma cells are available from ECACC [European Collection of Cell Cultures; Health Protection Agency, Porton Down; SP4 0JG Salisbury, Wiltshire UK] (human Caucasian lung carcinoma cell line COR-L23/R; deposit number ECACC 96042339).
  • HUVEC 8 ⁇ 10 3
  • VEGF vascular endothelial growth factor
  • Migration assays were performed on growth arrested confluent HUVEC or BAEC. Cell monolayers were wounded with a rubber policeman. The dishes were washed with serum-free medium and each well was photographed at 100 ⁇ magnification.
  • Dishes were then incubated for 16 h in serum free medium containing of sHLA-G1 or sHLA-G1mono (100 ng/ml) in the presence or not of VEGF (50 ng/ml). A second photograph of each well was taken and the cells which had migrated were counted by superposing the two photographs.
  • VEGF and sHLA-G1 were iodinated with the iodogen procedure with a specific activity of 240,000 and 110,000 cpm/ng, respectively (Plou ⁇ t, J., F. Moro, S. Bertagnolli, N. Coldeboeuf, H. Mazarguil, S. Clamens, and F. Bayard. 1997. Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect J Biol Chem 272:13390.). Wells containing 2 ⁇ 10 5 serum-starved HUVEC were either pre-treated with 50 ng/ml VEGF or sHLA-G1 at 37° C.
  • Growth factor reduced Matrigel (BD Biosciences) was diluted in collagen (1/6 v/v) and kept on ice. 160 ⁇ l of this solution was added to each well of 8-well culture slides precoated with type I rat tail collagen and left at 37° C. for 1 h. Following gel formation, a HUVEC suspension, mixed or not with control, FGF-2, sHLA-G1 or mAb CD160 was seeded on Matrigel/collagen gels for 24 h at 37° C. in a humidified 5% CO2 incubator.
  • Angiogenesis was quantified as previously described (Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzansld P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert J M, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C. “CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models”, Cancer Res. 2003 Sep. 15;63(18):5978-91; Erratum in: Cancer Res. 2003 Nov. 1;63(21):7543.
  • the culture medium was removed, cells rinsed twice with PBS and fixed for 30 min at room temperature in a 4% PFA solution. Then, the cells were washed twice with PBS and stained with Masson's Trichrom stain. The extent of the microcapillary network was measured using an automated computer-assisted image analysis system (Imagenia, Biocom, Les Ulis, France), and the total length of the capillaries in each well was determined. The mean microcapillary network length ( ⁇ m) was calculated for each experimental condition. Experiments were performed in triplicate and repeated 3 times.
  • HMVEC in normoxia or in hypoxia (24 hours incubated at 37° C. in a 5% O2 atmosphere) or HUVEC (Biowitthaker) were scrapped in PBS-BSA and incubated or not with 100 ng/ml of sHLA-G1 at 4° C. After 2 h cells were incubated with either CD8, CD85d, CD85j (Plou ⁇ t, J., F. Moro, S. Bertagnolli, N. Coldeboeuf, H. Mazarguil, S. Clamens, and F. Bayard. 1997. Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect.
  • CD160 transcripts were detected by RT-PCR using the following primers: 5′-3′ (sense) TGCAGGATGCTGTTGGAACCC (SEQ ID NO:1) and 3′-5′ (reverse) TCAGCCTGAACTGAGAGTGCCTTC (SEQ ID NO:2; cDNA quality was confirmed by amplification of ⁇ actin using the following primers: 5′-3′ GCGGGAAATCGTGCGTGCGTGACA (SEQ ID NO:3) and 3′-5′ GATGGAGTTGAAGGTAGTTTCGTG (SEQ ID NO:4). Amplification conditions for CD160 and ⁇ -actin were 95° C. for 45 s, 60° C. 30 s, and 72° C. for 1 min, for 35 cycles. For CD160 sequencing, a Taq High Fidelity was used (Invitrogen). PCR product was purified (qiaex II, Qiagen) and analyzed with the following primers:
  • BY01 (5′-3′ sense) (TGCAGGATGCTGTTGGAACCC; SEQ ID NO: 1), BY03 (3′-5′ reverse) (TCAGCCTGAACTGAGAGTGCCTTC; SEQ ID NO: 2; BY02 (5′-3′ sense) CAGCTGAGACTTAAAAGGGATC; SEQ ID NO: 5) and BY04 (3′-5′ reverse) (CACCAACACCATCTATCCCAG; SEQ ID NO: 6).
  • Sub-confluent Lewis lung carcinoma cells were trypsinized, washed twice and resuspended in PBS. 2.10 5 cells were inoculated subcutaneously into the right posterior lateral flank of anaesthetised (pentobarbital, IP) female C57B16 mice (IFFA CREDO, France). Mice were killed 21 days after cell injection with an overdose of pentobarbital; tumors were removed and fixed in 10% neutral buffered formalin (Sigma) overnight at 4° C., paraffin embedded (Embedder Leica) and then sectioned (5 ⁇ m) with a microtome (Leica). After rehydration (toluene/ethanol/PBS), slides were heated for 20 min in a citrate buffer solution at pH 6.1.
  • Sections were placed in a DAKO Autostainer and incubated with TNB Blocking buffer (TSA Kit, NEN), peroxidase-blocking reagent (Dako) and Mouse on Mouse immunoglobulin blocking reagent (Vector Laboratories). Tumours vessels were stained with the monoclonal antibody CL1-R2 at a final concentration of 10 ⁇ g/ml (Dilution 1/500 de la solution) during 30 min at room temperature. Sections were then incubated with biotin-labelled goat anti-rabbit IgG for 10 min followed by incubation with Avidin-Biotin Complex (Vector Laboratories) for 30 min.
  • Sections were then stained with DAB (Vector Laboratories) and counterstained with hematoxylin. Immunostained tissues were viewed on a Nikon microscope (E-800) and digitised using a DMX 1200 camera (Nikon) with 40 ⁇ objective.
  • sHLA-G1 Inhibits VEGF- or FGF2-Induced Endothelial Cell Proliferation, Migration and Capillary-Like Tube Formation
  • VEGF is the more potent mitogenic and motogenic factor for vascular EC. Therefore we investigated whether sHLA-G1 could interfere with VEGF functions on EC in vitro. We found that sHLA-G1 inhibited VEGF-induced proliferation of HUVEC ( FIG. 4A ) whereas it did not affect basal proliferation of these cells. In contrast, when sHLA-G1 was fused to ⁇ 2m, the single chain protein did not affect the proliferation of EC induced by VEGF, therefore suggesting that folding of the molecule was critical for its biological activity. Moreover, sHLA-G1 inhibited VEGF-induced proliferation of bovine EC derived from aorta or adrenal gland microvessels, suggesting a mechanism conserved among species and organ of origin of the EC.
  • the Matrigel was diluted with collagen to limit spontaneous angiogenesis which normally occurs after 3 days in culture. Morphology of the cells in Matrigel is shown in FIGS. 4C and the quantification of the total tubules length is shown in FIG. 4D . The results indicate that FGF-2 induced a potent angiogenic response and that addition of sHLA-G1 to FGF-2 significantly inhibited tube formation.
  • CD160 Receptor is Expressed By Endothelial Cells
  • HUVEC did not express CD8, nor CD85j. In contrast, these cells were strongly stained by an anti-CD160 mAb ( FIG. 6A ) like HMVEC.
  • FIG. 6A To provide additional evidence that CD160 was expressed by HUVEC, we performed RT-PCR analysis on these cells by comparison to CD160+(NK92) and CD160 ⁇ (CD4+ T) control cells, using CD160 specific primers. Similarly to NK92, CD160 mRNA was detected in HUVEC, whereas CD4+ T cells were negative ( FIG. 6B ). Then HUVEC and NK92 cDNAs were isolated and sequenced.
  • CD160-sHLA-G1 interaction was further evaluated by flow cytometry on HUVEC which were pre-incubated or not with sHLA-G1.
  • pre-incubation of HUVEC with sHLA-G1 down-modulated CD160 cell surface expression ( FIG. 7B ). This demonstrates that sHLA-G1 directly interacts with CD160 at the cell surface of HUVEC.
  • CD160-mAb cross-linking could mimic the sHLA-G1 anti-angiogenic activity.
  • CD160-mAb cross-linking leads to the inhibition of FGF2-mediated tubule vessel growth ( FIG. 8 ).
  • FIGS. 10A , 10 B, 10 C, 10 D we observed a strong staining for CD160 on EC in LLC tumors ( FIGS. 10A , 10 B, 10 C, 10 D) whereas no staining was observed with non-specific IgG.
  • Tumors cells did not express CD160 but EC of lymphatic vessels at the periphery of the tumor or microvessels inside the tumors express a high level of CD160.
  • CD160 triggers inhibition of VEGF- or FGF-2-induced in vitro angiogenesis upon engagement with its physiological ligand, sHLA-G1, or following specific mAb cross-linking (CL1-R2).
  • CD160 differs from the previously described CD36 receptor, a transmembrane glycoprotein bound by thrombospondin 1 (TSP-1), a potent inhibitor of angiogenesis (Dawson, D. W., S. F. Pearce, R. Zhong, R. L. Silverstein, W. A. Frazier, and N. P. Bouck. 1997. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 138:707.).
  • CD160 is a GPI-anchored molecule having no transmembrane domain, nor cytoplasmic tail (Anumantha, A., A. Bensussan, L. Boumsell, A. Christ, R.
  • sHLA-G1 was an EC CD160 ligand. Knowing that various HLA class I molecules may bind to CD160 (Le Bouteiller, P., A. Barakonyi, J. Giustiniani, F. Lieri, A. Marie-Cardine, M. Aguerre-Girr, M. Rabot, I. Hilgert, F. Mami-Chouaib, J. Tabiasco, L. Boumsell, and A. Bensussan. 2002. Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity.
  • NK natural killer
  • sHLA-G1 The anti-angiogenic activity of sHLA-G1 reported here is the first non immune function described to date. Spatial and temporal regulation of angiogenesis at the materno-fetal interface plays an important role in ensuring adequate blood supply to nourish the developing embryo, suggesting that there are local acting factors that regulate vascular growth (Ong, S., G. Lash, and P. N. Baker. 2000. Angiogenesis and placental growth in normal and compromised pregnancies. Baillieres Best Pract Res Clin Obstet Gynaecol 14:969.). sHLA-G1 is secreted by extravillous trophoblast, including endovascular trophoblast (Morales, P. J., J. L. Pace, J. S. Platt, T. A.
  • HLA-G2 Placental cell expression of HLA-G2 isoforms is limited to the invasive trophoblast phenotype. J Immunol 171:6215.) that replaces EC of the maternal spiral arteries, thereby increasing by several fold the diameter of these vessels (Loke, Y., and A. King. 2000. Immunology of implantation. Baillire's Clinical Obstetrics Gynaecology 14:827.).
  • hypoxia has been shown to regulate the expression of multiple angiogenic endothelial markers as CD54, CD105 or tie-2 receptor. Over-expression of tie-2 suggests that it is involved in a positive angiogenic response to hypoxia. Up-regulation of CD160 by hypoxia could be generate a negative regulation of angiogenesis and could prevent neovessels formation. Moreover, immunohistochemical on mouse tumor with CD160 antibody shows that this receptor is not expressed by tumor cells themselves but is expressed by EC of the tumoral vasculature. All these results demonstrate that CD160, up-regulated by hypoxia, is an inhibitory signaling receptor for angiogenesis and that its activation may be useful for experimental anti-angiogenic therapy to prevent tumoral cell growth.
  • CD160 is Not Restricted to the Cytotoxic T and NK Subset But is Also Expressed By CD4+ T Cells
  • PB-CD4+ cells Freshly isolated peripheral blood (PB)-CD4+ cells were obtained from lymphocytes of normal individual using the immunomagnetic CD4 cell isolation kit (Miltenyi Biotec). PB-CD4+ purity was shown to be >98% CD3+CD4+CD8 ⁇ by flow cytometry. PB-CD4+ were further cultured for several days (between 3 to 6 days) in a standard culture medium containing 10% of heat inactivated human AB serum supplemented with a high concentration of IL-15. The CD160 transcripts were detected by RT-PCR using the following primers:
  • FIG. 11 illustrative results are shown on FIG. 11 .
  • 0.2 ⁇ 10 6 cells were seeded into a 6 wells/plate, serum-starved for 24 h and then treated with sHLA-G1 (1 ⁇ g/ml), CL1-R2 mAb CD160 (10 ⁇ g/ml) or control Ig-G1 (10 ⁇ g/ml) for 50 h in the presence of VEGF (50 ng/ml).
  • sHLA-G1 1 ⁇ g/ml
  • CL1-R2 mAb CD160 10 ⁇ g/ml
  • control Ig-G1 10 ⁇ g/ml
  • the floating cells were collected by centrifugation, whereas adherent cells were harvested by trypsin-EDTA solution to produce a single cell suspension. The cells were then pelleted by centrifugation and washed twice with PBS.
  • Apoptotic cell death was identified by double staining with recombinant FITC (fluorescein isothiocyanate)-conjugated Annexin-V and PI (propidium iodide), using the Annexin V-FITC Apoptosis Detection kit (DAKO) according to manufacturer's instructions.
  • FITC fluorescein isothiocyanate
  • Annexin V-FITC Apoptosis Detection kit DAKO
  • Cells were analyzed by flow cytometry on a FACScan (Becton Dickinson) using the fluorescence 1 (FL1) signal detector for FITC conjugates and the FL3 signal detector for PI. Teen thousand events were recorded for each sample. The data were analyzed using CellQuest software.
  • FIG. 18 a demonstrates that CD160 receptor is expressed on the cell surface of HUVEC and HMVEC but not of human fibroblast in primary culture nor smooth muscle cells.
  • FIG. 18 b demonstrates that CL1-R2 triggers specific apoptosis of HUVEC and not fibroblasts.
  • FIG. 18 c indicate that the CL1-R2 anti-CD160 monoclonal antibody mimics the anti-angiogenic effect of the soluble HLA-G1 natural ligand of CD160.
  • Both soluble HLA-G1 as well as the anti-CD60 monoclonal antibody mediate endothelial cell (HUVEC) specific apoptosis, the IgG1 isotype control being inefficient Accordingly, Annexin V binding experiments establish the specificity of this effect: the CL1-R2 monoclonal antibody induces apoptosis of CD160 expressing HUVEC but not of CD160 negative primary fibroblast.
  • HLA-G is a Major Histocompatibility Complex class Ib molecule whose constitutive tissue distribution is mainly restricted to trophoblast cells at the maternal-fetal interface during pregnancy.
  • soluble HLA-G1 sHLA-G1
  • sHLA-G1 soluble HLA-G1
  • sHLA-G1 induces apoptosis through binding to CD160, a glycosylphosphatidylinositol-anchored receptor expressed by endothelial cells.
  • CL1-R2 anti-CD160 monoclonal antibody mimics sHLA-G1-mediated inhibition of endothelial cell tube formation and induction of apoptosis.
  • engagement of CD160 in endothelial cells may be essential for the inhibition of angiogenesis.
  • sHLA-G1/CD160-mediated anti-angiogenic property may participate in the vascular remodeling of maternal spiral arteries during pregnancy, and offers an attractive therapeutic target to prevent pathologic neovascularization as we found that CD160 is strongly expressed in the vasculature of a murine tumor.
  • HLA-G is a human major histocompatibility class Ib gene characterized by a unique promoter region, limited polymorphism, restricted constitutive tissue distribution and the occurrence of several spliced transcripts encoding either membrane-bound or soluble proteins 1 .
  • the actively secreted soluble HLA-G1 (sHLA-G1) isoform derives from mRNA retaining intron 4 2 , which contains a stop codon that precludes translation of the transmembrane domain.
  • This 37 kDa intron-retaining sHLA-G1 isoform associates with ⁇ 2-microglobulin ( ⁇ 2m) 2 .
  • sHLA-G1 The predominant expression of sHLA-G1 in the placenta at a time when polymorphic HLA-A and HLA-B class Ia molecules are repressed is consistent with important immunological functions during pregnancy 3 .
  • sHLA-G1 induces apoptosis of activated CD8+ T and NK cells 4,5 and down-regulates CD4+ T cell allo-proliferation response 6 .
  • mAb monoclonal antibodies
  • HLA-G a defect of HLA-G expression in extravillous cytotrophoblast is associated with preeclampsia 9,10 , a common complication of pregnancy in which HLA-G + endovascular trophoblast invasion of maternal spiral arteries is abrogated, compromising blood flow to the maternal interface 9 ;
  • HLA-G inhibited the transendothelial migration of NK cells 11 and the rolling adhesion of activated NK cells on endothelial cells 12 .
  • the potential role of sHLA-G1 in the modulation of angiogenesis has not been addressed.
  • Angiogenesis the formation of new capillaries from preexisting blood vessels, is a crucial component of embryonic vascular development and differentiation, wound healing, and organ regeneration, but it also contributes to the progression of pathologies that depends on neovascularization, including tumor growth, diabetes, ischemic ocular disease, and rheumatoid arthritis 13-15 . While the most important mediators of angiogenesis, the endothelial growth factor (VEGF) and the fibroblast growth factor (FGF) families are well defined 16 , angiogenesis exists as a complex process involving multiple gene products expressed by different cell types, all contributing to an integrated sequence of events 17 .
  • VEGF endothelial growth factor
  • FGF fibroblast growth factor
  • sHLA-G1 is a regulator of endothelial cell activity
  • sHLA-G1 inhibits VEGF- and FGF-induced angiogenesis and induces apoptosis of endothelial cells by interaction with the glycosylphosphatidylinositol (GPI)-anchored CD160 receptor18,19 expressed on endothelial cells.
  • GPI glycosylphosphatidylinositol
  • sHLA-G1 Inhibits VEGF- or FGF2-Mediated Endothelial Cell Proliferation, Migration and Capillary Tubule Formation
  • VEGF is the most potent mitogenic and motogenic factor for endothelial cells 16 . Therefore, we investigated whether sHLA-G1 could interfere with VEGF functions in vitro. Purified recombinant sHLA-G1, when added exogenously to HUVEC, inhibited the proliferative response to VEGF in a dose-dependent manner ( FIG. 12 a ). In contrast, the single chain protein sHLA-G1 fused to ⁇ 2m (sHLA-G1mono) had no effect, indicating that folding of sHLA-G1 was critical for its biological activity.
  • sHLA-G1 also inhibited VEGF-mediated proliferation of bovine endothelial cells derived from aorta or adrenal gland microvessels (data not shown), suggesting a mechanism conserved among species and endothelial cells originating from different tissues.
  • HUVEC expressed some of the HLA-G receptors described to date, including CD8 4 , CD85d 21 , CD85j 21 , and CD160 22 .
  • Flow cytometry analysis revealed that HUVEC were stained by anti-CD160 mAb, although not with constant levels, but not by anti-CD8, -CD85d nor -CD85j mAbs ( FIG. 15 a ).
  • HMVEC also bound anti-CD160 mAb ( FIG. 15 a ), as did bovine endothelial cells (data not shown), suggesting that the CD160 epitope recognized by the mAb was conserved among species.
  • sHLA-G1 did effectively bind to the CD160 receptor expressed by endothelial cells.
  • a HLA-G1 tetramer specifically bound to HUVEC like it did on CD160-transfected Jurkat FIG. 17 a .
  • sHLA-G1-CD160 direct interaction on HUVEC was further demonstrated by showing that pre-incubation of HUVEC with recombinant sHLA-G1 specifically blocks the binding of anti-CD160 mAb ( FIG. 17 b ), whereas a pre-incubation with VEGF did not (data not shown).
  • sHLA-G1 could exert a non immune function, namely angiogenesis inhibition.
  • Spatial and temporal regulation of the vasculature at the maternal-fetal interface plays an important role in ensuring adequate blood supply to nourish the developing embryo, suggesting that there are locally acting factors that regulate vascular cells 23 .
  • sHLA-G1 is secreted by extravillous trophoblast, including endovascular trophoblast 3 that replaces endothelial cells and remodels the maternal spiral arteries, thereby increasing the diameter of these vessels several fold 24 .
  • endovascular trophoblast 3 that replaces endothelial cells and remodels the maternal spiral arteries, thereby increasing the diameter of these vessels several fold 24 .
  • HLA-G expression including diminishment of soluble HLA-G in preeclamptic placentas, characterized by a shallow cytotrophoblast invasion and a reduced flow of maternal blood to the feto-placental unit 9,10 , favors such hypothesis.
  • angiogenesis inhibitors including induction of endothelial cell apoptosis 25 , inhibition of matrix metalloproteinase activity 26 , or chemorepulsion of endothelial cells 27 .
  • sHLA-G1 novel inhibitory actions of sHLA-G1, including significant blockade of endothelial cell migration, proliferation and vessel formation.
  • these effects may involve induction of endothelial cell apoptosis since sHLA-G1-treated endothelial cells progressively showed apoptotic morphology.
  • sHLA-G1 The direct inhibitory effect of sHLA-G1 on vessel formation is most likely mediated through the functional CD160 receptor, as the CL1-R2 anti-CD160 mAb mimics the inhibition of FGF-2-induced capillary tubule formation by endothelial cells cultured in Matrigel and the induction of endothelial apoptosis.
  • angiogenesis inhibitors like semaphorin 3F which is a competitor of VEGF binding to neuropilin receptor 27
  • sHLA-G1 acts directly on CD160 receptor. Knowing that various HLA class I molecules may bind to CD160 29 , it cannot be excluded that other soluble MHC class I molecules could also trigger this receptor to exert anti-angiogenic functions.
  • CD160 as an inhibitory signaling receptor for angiogenesis could be useful for experimental anti-angiogenic therapy to prevent tumor cell growth.
  • Our immunohistochemical analysis of a mouse graft tumor showed that CD160, encoded by a gene conserved in this species 31 , was present in endothelial cells of the tumoral vasculature but was not expressed by tumor cells. Future goals are therefore to examine the potential CD160/sHLA-G1 mediated anti-angiogenic effect in different tumors and explore the possible therapeutic use of CD160 in the regulation of pathological neovascularization.
  • HMVEC Human umbilical vein endothelial cells
  • HMVEC human microvascular endothelial cells
  • EBM BioWhittaker
  • FCS 5% FCS
  • FGF-2 R & D systems, Minneapolis, Ill.
  • SGHEC-7 cells are a HUVEC-derived cell line, cultured as previously described 32 .
  • Porcine aortic endothelial cell (PAEC)-VEGF-R2 (KDR), PAEC-NPL1 transfectants, human Jurkat T cells and Jurkat transfected with CD160 (Jurkat-CD160) 29 were produced locally.
  • NK92 is a human NK cell line expressing CD160 29 .
  • CD4 + T cells were purified from PBMC using the MACS separation system (Miltenyi Biotec, Auburn, Calif.).
  • Prostate adenocarcinoma PC3 cells transfected with PCDNA vector containing intron 4-retaining sHLA-G1 cDNA and PC3 cells transfected with empty vector (PC3-neo) 33 were grown to confluence for 4 days and conditioned media collected. Media was removed, centrifuged to remove cell debris and stored at ⁇ 20° C.
  • the sHLA-G1- ⁇ 2m fusion monochain gene was engineered by connecting the last residue of the ⁇ 3 domain of HLA-G to the first codon of the human ⁇ 2m sequence through a 15-residue space 34 .
  • sHLA-G1 and sHLA-G1mono were purified from eukaryotic cell culture supernatants, using immunoaffinity columns, as previously described 34 .
  • VEGF 165 was expressed in a baculovirus system as described 35 .
  • mAbs used included CL1-R2 (IgG1) anti-BY55/CD160 29 , produced in one of our laboratories, anti-CD8 (OKT8, Coulter Immunotech), anti-ILT4/CD85d (gift of M.
  • HLA-G1 tetramers were produced essentially as previously described 36 , using synthetic self-peptide RIIPRHLQL 37 and after addition of streptavidin-PE (Pharmingen). Labeling of HUVEC, Jurkat and Jurkat-CD160 by PE-conjugated HLA-G tetramers was performed at 37° C. for 1 h. For Jurkat-CD160 and Jurkat, tetramers were cross-linked with anti-HLA class I W6/32 mAb, as previously described 22 .
  • Endothelial cell proliferation and migration assays were performed using 12-well plates (8,000 cells/well) coated with 0.3% gelatin in PBS. Cells were incubated with saline or VEGF (1 ng/ml) in the presence or absence of various concentrations of sHLA-G1 or sHLA-G1mono. Seven days later, cells were trypsinized and counted using a Coulter counter ZM. Migration assays were performed on growth arrested confluent HUVEC or BAEC. Cell monolayers were wounded with a rubber policeman, washed with serum-free medium and each well was photographed at 100 ⁇ magnification.
  • Dishes were then incubated for 16 h in serum free medium containing of sHLA-G1 or sHLA-G1mono (100 ng/ml) in the presence or not of VEGF (50 ng/ml). A second photograph of each well was taken and the cells which had migrated were counted by superposing the two photographs.
  • VEGF and sHLA-G1 cell binding Purified recombinant VEGF and sHLA-G1 were radiolabelled with Na 125 I to a specific activity of 2,4 ⁇ 10 4 and 1,1 ⁇ 10 5 cpm/ng, respectively 35 .
  • Wells containing 2 ⁇ 10 5 serum-starved HUVEC were either pre-treated with 50 ng/ml of VEGF or sHLA-G1 at 37° C. for various time intervals (0.1-24 h) or processed immediately for binding assays. Briefly, dishes were rinsed in cold DMEM supplemented with 0.2% gelatin and 20 mM Hepes (pH 7.3) and incubated at 4° C.
  • the cells were washed twice with PBS and stained with Masson's Trichrome.
  • the extent of the microcapillary network was measured using an automated computer-assisted image analysis system (Imagenia, Biocom), and the total length of the capillaries in each well was determined.
  • the mean microcapillary network length ( ⁇ m) was calculated for each experimental condition. Experiments were performed in triplicate and repeated three times.
  • HUVEC or HVMEC were scraped in PBS-EDTA and incubated in the presence or absence of 100 ng/ml of sHLA-G1 at 4° C. After 2 h, cells were incubated with anti-CD8, -CD85d, -CD85j, -CD106 or CL1-R2 anti-CD160 specific mAbs or Ig-isotype control (20 ⁇ g(ml) followed by F(ab′) 2 -FITC- or PE-conjugated anti-mouse IgG. Non-viable cells were excluded by the use of propidium iodide. Samples were analyzed on a Coulter-Epics ELITE flow cytometer.
  • CD160 transcripts were detected by RT-PCR using the following primers: 5′-TGCAGGATGCTGTTGGAACCC-3′ (SEQ ID NO: 8) and 3′-TCAGCCTGAACTGAGAGTGCCTTC-5′ (SEQ ID NO: 9).
  • cDNA quality was confirmed by amplification of ⁇ -actin using the appropriate primers.
  • Amplification conditions for CD160 and ⁇ -actin were 95° C. for 45 s, 60° C. 30 s, and 72° C. for 1 min.
  • a Taq High Fidelity was used (Invitrogen).
  • PCR product was purified (qiaex II, Qiagen) and analyzed with the following primers:
  • BY01 (5′-TGCAGGATGCTGTTGGAACCC-3′ (SEQ ID NO: 8)
  • BY03 (3′-TCAGCCTGAACTGAGAGTGCCTTC-5′ (SEQ ID NO: 9)
  • BY02 (5′-CAGCTGAGACTTAAAAGGGATC-3′ (SEQ ID NO: 5)
  • BY04 (3′-CACCAACACCATCTATCCCAG-5′ (SEQ ID NO: 6)).
  • Sections were incubated with CL1-R2 anti-CD160 mAb (10 ⁇ g/ml), followed by biotin-labeled goat anti-mouse IgG and avidin-biotin complex (Vector Laboratories). They were stained with DAB (Vector Laboratories), counterstained with hematoxylin, viewed on a Nikon microscope (E-800) and digitized using a DMX 1200 camera (Nikon) with 40 ⁇ objective.
  • SGHEC-7 cells were seeded into 6-well plates (2.5 ⁇ 10 5 cells/well in normal culture medium. After 15 h, conditioned media from PC3-sG1 or PC3-neo cells, recombinant sHLA-G1 (100 ng/ml), CL1-R2 anti-CD160 mAb (1-10 ⁇ g/ml), IgG1 isotype control (10 ⁇ g/ml) or zVAD-fink (50 ⁇ mol/l, Calbiochem) were added to the wells. The plate was transferred to an Olympus IX70 inverted fluorescence microscope with motorized stage and cooled CCD camera and enclosed in a heated, humidified chamber at 37° C.
  • SGHEC-7 endothelial cells were seeded in culture plates. After 16 h the cells were stimulated with recombinant sHLA-G1 (100 ng/ml) for 60 h. Cells were lysed in RIPA buffer with 0.1 mg/ml PMSF, 30 ⁇ l/ml aprotinin, and 1 mmol/l sodium orthovanadate at 4° C. for 30 min. The samples were separated by SDS-PAGE and transferred to a nitrocellulose membrane. Following incubation in blocking buffer for 1 h at room temperature, the membrane was incubated with rabbit polyclonal anti-human cleaved PARP (Promega) for 1 h. Anti-rabbit IgG peroxidase (A6154, Sigma) was added for 1 h. Detection of membrane bound antibodies was carried out by chemiluminescence (ECLPlus, Amersham).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
US11/659,749 2004-08-09 2005-08-09 Angiogenic and immunoglobic applications of anti cd160 specific compounds obtainable from mab cl 1-r2 Abandoned US20090317401A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04292015A EP1626059A1 (fr) 2004-08-09 2004-08-09 Applications angiogéniques et immunologiques de composés spécifiques anti-CD160 pouvant être obtenus à partir de l'anticorps monoclonal CL1-R2
EP04292015.7 2004-08-09
PCT/EP2005/009231 WO2006015886A1 (fr) 2004-08-09 2005-08-09 Applications angiogénique et immunologique de composés d'anticorps-cd 160 spécifiques obtenus à partir de l’anticorps monoclonal cl1-r2

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/009231 A-371-Of-International WO2006015886A1 (fr) 2004-08-09 2005-08-09 Applications angiogénique et immunologique de composés d'anticorps-cd 160 spécifiques obtenus à partir de l’anticorps monoclonal cl1-r2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/175,221 Division US8444978B2 (en) 2004-08-09 2011-07-01 Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2

Publications (1)

Publication Number Publication Date
US20090317401A1 true US20090317401A1 (en) 2009-12-24

Family

ID=34931332

Family Applications (4)

Application Number Title Priority Date Filing Date
US11/659,749 Abandoned US20090317401A1 (en) 2004-08-09 2005-08-09 Angiogenic and immunoglobic applications of anti cd160 specific compounds obtainable from mab cl 1-r2
US13/175,221 Active US8444978B2 (en) 2004-08-09 2011-07-01 Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2
US13/861,749 Abandoned US20140120110A1 (en) 2004-08-09 2013-04-12 ANGIOGENIC AND IMMUNOLOGIC APPLICATIONS OF ANTI-CD160 SPECIFIC COMPOUNDS OBTAINABLE FROM mAb CL1-R2
US14/325,833 Abandoned US20150004170A1 (en) 2004-08-09 2014-07-08 Angiogenic and Immunologic Applications of Anti-CD160 Specific Compounds Obtainable From mAb CL1-R2

Family Applications After (3)

Application Number Title Priority Date Filing Date
US13/175,221 Active US8444978B2 (en) 2004-08-09 2011-07-01 Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2
US13/861,749 Abandoned US20140120110A1 (en) 2004-08-09 2013-04-12 ANGIOGENIC AND IMMUNOLOGIC APPLICATIONS OF ANTI-CD160 SPECIFIC COMPOUNDS OBTAINABLE FROM mAb CL1-R2
US14/325,833 Abandoned US20150004170A1 (en) 2004-08-09 2014-07-08 Angiogenic and Immunologic Applications of Anti-CD160 Specific Compounds Obtainable From mAb CL1-R2

Country Status (10)

Country Link
US (4) US20090317401A1 (fr)
EP (2) EP1626059A1 (fr)
JP (1) JP5162239B2 (fr)
AT (1) ATE475674T1 (fr)
CA (1) CA2576627C (fr)
DE (1) DE602005022589D1 (fr)
DK (1) DK1776387T3 (fr)
ES (1) ES2349015T3 (fr)
PL (1) PL1776387T3 (fr)
WO (1) WO2006015886A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013074738A1 (fr) * 2011-11-15 2013-05-23 Sanford-Burnham Medical Research Institute Compositions et procédés pour le traitement de maladies autoimmunes et inflammatoires
US20150344572A1 (en) * 2010-05-28 2015-12-03 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-cd160 specific antibodies for the treatment of eye disorders based on neoangiogenesis

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101351554B (zh) 2005-10-04 2016-05-18 索利金尼克斯公司 包括通过调节先天免疫治疗和预防感染在内的治疗和预防免疫相关疾病的新型肽
EP1880729A1 (fr) * 2006-07-20 2008-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation de CD160 soluble pour la suppression de l'immunité
EP2210903A1 (fr) 2009-01-21 2010-07-28 Monoclonal Antibodies Therapeutics Anticorps monoclonaux anti-CD 160 et leurs utilisations
US11186635B2 (en) 2016-10-25 2021-11-30 Institut National De La Santé Et De La Recherché Médical (Inserm) Monoclonal antibodies binding to the CD160 transmembrane isoform
FR3061716B1 (fr) 2017-01-06 2019-05-17 Elsalys Biotech Nouveaux composes ciblant le cd160 humain
EP3898677A1 (fr) 2018-12-21 2021-10-27 OSE Immunotherapeutics Molécule bifonctionnelle anti-pd-1/il -7
WO2020165374A1 (fr) 2019-02-14 2020-08-20 Ose Immunotherapeutics Molécule bifonctionnelle comprenant il-15ra
WO2021122866A1 (fr) 2019-12-17 2021-06-24 Ose Immunotherapeutics Molécules bifonctionnelles comprenant un variant de l'il-7
WO2022013256A1 (fr) 2020-07-15 2022-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation de cd160 en tant que biomarqueur dans la leucémie aiguë myéloïde
EP4225792A1 (fr) 2020-10-08 2023-08-16 Affimed GmbH Lieurs trispécifiques
GB202103706D0 (en) * 2021-03-17 2021-04-28 Ucl Business Ltd CD160 binding domain
WO2022214652A1 (fr) 2021-04-09 2022-10-13 Ose Immunotherapeutics Échafaudage pour molécules bifonctionnelles comprenant des domaines de liaison pd-1 ou cd28 et sirp
WO2022214653A1 (fr) 2021-04-09 2022-10-13 Ose Immunotherapeutics Nouvel échafaudage pour molécules bifonctionnelles présentant des propriétés améliorées
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
WO2023170207A1 (fr) 2022-03-09 2023-09-14 Alderaan Biotechnology Anticorps d'isoforme transmembranaire anti-cd160
WO2023222886A1 (fr) 2022-05-20 2023-11-23 Depth Charge Ltd Protéines de fusion anticorps-cytokine
WO2024028386A1 (fr) 2022-08-02 2024-02-08 Ose Immunotherapeutics Molécule multifonctionnelle dirigée contre cd28
WO2024056862A1 (fr) 2022-09-15 2024-03-21 Avidicure Ip B.V. Protéines multispécifiques de liaison à l'antigène pour le ciblage tumoral de cellules nk et leur utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194549B1 (en) * 1993-08-27 2001-02-27 Dana-Farber Cancer Institute Natural killer cell-specific antigen and antibodies that identify the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5253898A (en) * 1996-11-12 1998-06-03 Dana-Farber Cancer Institute Recombinant by55 and nucleic acids encoding same
WO2001036630A2 (fr) * 1999-11-15 2001-05-25 Innate Pharma S.A.S. Nouveau recepteur de declenchement implique dans la cytotoxicite naturelle induite par les lymphocytes tueurs naturels (nk) et anticorps permettant de l'identifier
FR2828403B1 (fr) * 2001-08-07 2003-10-17 Abtech Utilisation de molecules solubles hla de classe 1 pour la preparation de compositions pharmaceutiques utiles pour inhiber l'angiogenese
CA2501940A1 (fr) * 2002-10-09 2004-04-22 Tolerrx, Inc. Molecules preferablement associees aux cellules t effectrices ou aux cellules t regulatrices et procedes d'utilisation de ces molecules

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194549B1 (en) * 1993-08-27 2001-02-27 Dana-Farber Cancer Institute Natural killer cell-specific antigen and antibodies that identify the same

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150344572A1 (en) * 2010-05-28 2015-12-03 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-cd160 specific antibodies for the treatment of eye disorders based on neoangiogenesis
KR101847572B1 (ko) 2010-05-28 2018-05-24 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 신혈관신생에 기초한 안 질환 치료용 항-ｃｄ160 특이적 항체
US10208124B2 (en) * 2010-05-28 2019-02-19 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-CD160 specific antibodies for the treatment of eye disorders based on neoangiogenesis
WO2013074738A1 (fr) * 2011-11-15 2013-05-23 Sanford-Burnham Medical Research Institute Compositions et procédés pour le traitement de maladies autoimmunes et inflammatoires
US20130164306A1 (en) * 2011-11-15 2013-06-27 Sanford-Burnham Medical Research Institute Compositions and methods for treating autoimmune and inflammatory disorders
US9982023B2 (en) * 2011-11-15 2018-05-29 Sanford-Burnham Medical Research Institute Compositions and methods for treating autoimmune and inflammatory disorders
US10717765B2 (en) 2011-11-15 2020-07-21 Sanford Burnham Prebys Medical Discovery Institute Compositions and methods for treating autoimmune and inflammatory disorders
US11365221B2 (en) 2011-11-15 2022-06-21 Sanford Burnham Prebys Medical Discovery Institute Compositions and methods for treating autoimmune and inflammatory disorders

Also Published As

Publication number Publication date
WO2006015886A1 (fr) 2006-02-16
ATE475674T1 (de) 2010-08-15
DK1776387T3 (da) 2010-11-22
JP2008517873A (ja) 2008-05-29
EP1626059A1 (fr) 2006-02-15
CA2576627A1 (fr) 2006-02-16
JP5162239B2 (ja) 2013-03-13
EP1776387A1 (fr) 2007-04-25
ES2349015T3 (es) 2010-12-21
PL1776387T3 (pl) 2011-01-31
US20120003224A1 (en) 2012-01-05
US8444978B2 (en) 2013-05-21
US20150004170A1 (en) 2015-01-01
DE602005022589D1 (de) 2010-09-09
EP1776387B1 (fr) 2010-07-28
US20140120110A1 (en) 2014-05-01
CA2576627C (fr) 2014-02-18

Similar Documents

Publication Publication Date Title
US8444978B2 (en) Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2
JP6968872B2 (ja) 抗Ｔｉｍ−３抗体
Fons et al. Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells
US6852320B2 (en) T cell inhibitory receptor compositions and uses thereof
EP0970128A1 (fr) Peptides immunotherapeutiques se liant a ctla-4
CN111511760A (zh) 对btn2具有特异性的抗体及其用途
JP4776845B2 (ja) ヒトナチュラルキラー細胞によって媒介される天然細胞毒性に関連した新規トリガリングレセプターおよび同一の性質を有する抗体
JP2007525416A5 (fr)
US20220372159A1 (en) Treatment and Prevention of Ischemic Diseases And/Or Ischemic Tissue Damages
JP2944218B2 (ja) Ｐｄｇｆレセプタに対する抗体を使用した脈管内膜過形成の阻害
CA2733529A1 (fr) Anticorps modulant la differenciation et la fonction de cellules dendritiques par la molecule d'adhesion intercellulaire de liaison-1 et son utilisation
Gozalbo López et al. The MHC-related protein 1 (MR1) is expressed by a subpopulation of CD38+, IgA+ cells in the human intestinal mucosa
US20240166760A1 (en) MOLECULES THAT BIND TO CD66e POLYPEPTIDES
JP2019099492A (ja) 抗ヒトｉｌ−２６抗体
CA3238936A1 (fr) Anticorps contre ctla-4 et leurs methodes d'utilisation
WO2023114176A2 (fr) Molécules se liant à des polypeptides hétérodimères cd94/nkg2a
WO1995035120A1 (fr) Anticorps monoclonaux destines a reduire les reactions immunes anti-heterologues
CN115322257A (zh) Bcma靶向抗体、嵌合抗原受体及其应用
CA2288307C (fr) Recepteur activateur nouveau entrant en jeu dans la cytoxicite naturelle induite par les cellules nk humaines et anticorps revelant sa presence
Fournel et al. Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and
Moretta et al. Pre-clinical characterization of 1-7F9, a novel human anti-KIR therapeutic
MXPA99001388A (en) Methods and means for modifying complement activation
MXPA06002968A (en) Modulators of p-selectin glycoprotein ligand 1

Legal Events

Date Code Title Description
AS Assignment

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA REC

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BENSUSSAN, ARMAND;BOUMSELL, LAURENCE;LEBOUTEILLER, PHILIPPE;REEL/FRAME:020856/0001;SIGNING DATES FROM 20060207 TO 20070206

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION